Sunday September 6 2015

Sunday, September 6, 2015 


07:00 - 11:00 International Thoracic Oncology Nursing Forum (ITONF) Workshop (Ticketed 

Session)* 

Chair: Beth Ivimey, Australia 

Room: 201 + 203 

Meeting the Needs of Nurses… 

The ITONF are delighted to present this workshop. Officially launched at the 

WCLC 2011 Conference in Amsterdam, ITONF aims to be an internationally 

recognized body of expert knowledge in thoracic oncology nursing. It provides 

members with leadership, a united voice, support, education and a unique 

forum to network internationally. This interactive workshop will provide an 

excellent opportunity for learning, sharing of knowledge as well as networking, 

and renewal of friendships. Nurses at all levels involved in the delivery of care to 

patients with lung cancer will find this workshop stimulating and informative. 

Attendance will provide the opportunity to network with other nurses 

interested in lung cancer with outcomes from this workshop will provide 

direction for the future work of the ITONF Steering Committee. 

 

 

 

 

 

 

 

 

Registration Opens (Breakfast provided) 

Welcome: ITONF Chair - Beth Ivimey, Australia 

Sympton Burden in Lung Cancer: Key note Speaker - Rebecca Lehto, 

USA 

Update on Positive Impact of Specialist Lung Cancer Nurses on Better 

Patient Outcomes - Angela Tod, United Kingdom 

Management of Toxicity of TKIs in a Nurse Practitioner Clinic - Michelle 

Turner ,USA 

Early Intervention - John McPhelim, United Kingdom 

Lung Cancer in Vulnerable Populations - Anne Fraser, New Zealand 

Radiation Induced Oesophagitis and Management - Mary Duffy, 

Australia 

*Registration fee: 25 USD 

07:30 - 11:00 Thoracic Alliance for Cancer Trials (TACT) Meetings 

Chair: Paul Mitchell, Australia 

Room: 205 + 207 

TACT is an emerging international non-profit umbrella organisation for 

academic research groups from around the world, dedicated to facilitating 

thoracic oncology research. Meetings will focus on discussion of progress 

updates as well as clinical research proposals. 

 

 

Steering Committee Meeting (Closed) - Paul Mitchell, Australia 

TACT Group Leaders' Meeting - Paul Mitchell, Australia 

3


07:30 - 11:00 Pancake Fun Walk 

 

Location: Sculpture Park, across the street from Colorado Convention 

Center, Champa and North Speer Blvd 

07:30 - 10:30 Joint IASLC – Chinese Society for Clinical Oncology – Chinese Alliance Against 

Lung Cancer Session* 

Supported by the China Health Promotion Foundation: 

Track: Joint Chinese/English Session 

Chairs: ChunXue Bai, China & Yi-Long Wu, China 

Room: Mile High Ballroom 1a - 1f 

Introduction - ChunXue Bai, China & Yi-Long Wu, China 

Molecular Epidemiology of Lung Cancer in China - Baohui Han, China 

Development of New Drugs by Chinese Pharmaceutical Companies - 

Qing Zhou, China 

Current Status of Molecular Testing in China: Application and 

Technology - Shun Lu, China 

Asian Contributions to Global Drug Development - Tony Mok, Hong 

Kong 

New Diagnostic Techniques for Lung Cancer - ChunXue Bai, China 

Oral Abstract Session (3 Abstracts and 1 Discussion) - Discussant: Yilong 

Wu, China 

Overview the Publishing of Cancer Special Issue - ChunXue Bai, China 

Challenges of Tobacco Related Lung Cancer in China - Suresh 

Ramalingam, USA 

Progress of Management for Lung Cancer: Focus on China - Jie Hu, 

China 

* Simultaneous translation English ↔ Mandarin provided 

07:30 - 11:00 YIS: Young Investigator Session: Q & A with Longstanding IASLC Members 

Track: YIS 

Chairs: Laurie Carr, USA & James Jett, USA 


 

 

 

 

Introduction to IALSC: What It Can Do For You - David Carbone, USA 

Planning an Academic Career in Lung Cancer - Heather Wakelee, USA 

How to Write a Grant Application for Young Investigators - Steven 

Dubinett, USA 

How to Get Your Paper Published - Alex Adjei, USA 

4


 

 

 

How to Present Data at a Conference - Tony Mok, Hong Kong 

Making the Most of the WCLC: A Guide for First Time Attendees - Silvia 

Novello, Italy 

Q&A with Longstanding IASLC Members - Paul A. Bunn, Jr, USA & 

Desmond Carney, Ireland & Frances Shepherd, Canada & Masahiro 

Tsuboi, Japan 

08:00 - 11:00 Workshop: Fact and Myth of Pleural Effusion in Lung Cancer Patient (Ticketed 

Session)* - FULL 

Room: 102 + 104 + 106 

This workshop is now FULL 

3 hour workshop that includes didactic lectures on Pleuroscopy for the 

evaluation of cancer patients with pleural effusions; Pleurodesis and Indwelling 

Pleural Catheters as palliation measures; and surviving pleural effusion in lung 

cancer. Lectures are followed by hands on practice in pleuroscopy and 

indwelling pleural catheters. 

 

 

 

 

 

Fact and Myth of Pleuroscopy for Pleural Effusion in Lung Cancer - Pyng 

Lee, Singapore 

Fact and Myth of Pleurodesis and Indwelling Pleural Catheter for 

Malignant Pleural Effusion - Fabian Maldonado, USA 

HANDS ON: Assigned into Groups 

1 IPC Station: 2 Models and IPC Sets - TBA 

1 Olympus Flex-Rigid Pleuroscopy Stations and 2 Models - Pyng Lee, 

Singapore 


09:00 - 11:00 Workshop: Contouring for Radiation Treatment Planning of Lung Cancer 

(Ticketed Session)* 

Room: 601 + 603 

Important additional information: Early registration is encouraged. After 

registration, weekly emails with contouring homework exercises will be sent 

directly to the participant. To get the most from this workshop, the participant 

will complete and submit their contouring homework exercises as instructed, 

prior to the workshop, and are encouraged to bring their laptop to the 

workshop for post didactic contouring exercises. 


**Max. 100 attendees 

11:00 - 13:00 Navigation Bronchoscopy Workshop (Ticketed Session)* 

Chairs: Ali I. Musani, USA 

Faculty: Kendra Hammond, USA & Pyng Lee, Singapore 

5

Monday, September 7, 2015 


07:00 - 08:00 Symposium supported by Helsinn Therapeutics, Inc.: Finding Solutions to 

Difficult Problems in Lung Cancer: Treatment of Cancer Cachexia 

Rooms: 601 + 603 

 

Webpage: www.prIMEoncology.org/nsclc_cachexia_denver2015 

Target audience: This educational activity is specifically designed for medical, 

radiation, and surgical oncologists and other healthcare professionals interested 

and/or involved in the treatment of cancer cachexia in patients with non-small 

cell lung cancer (NSCLC). 

Symposium supported by AstraZeneca: Transforming Advanced Lung Cancer 

Into a Chronic Disease: Answering Key Questions 

Rooms: 205 + 207 

 

Webpage: www.prIMEoncology.org/2015nsclcdenver 

Target audience: This activity is designed to meet the needs of medical 

oncologists, surgical and radiation oncologists, pulmonologists, pathologists, 

and other healthcare professionals involved in the treatment of patients with 

NSCLC. 

Symposium supported by Biodesix: Blood-Based Biomarkers to Guide the 

Treatment of Advanced NSCLC 

Speaker: Leora Horn, USA 

Room: Mile High Ballroom 2a - 3b 

For some time now, the oncology community has been seeking easily accessible, 

non-invasive methods to identify molecular alterations and biomarkers that 

characterize advanced cancer. Following tissue diagnosis for advanced lung 

cancer, there may be insufficient tissue for further molecular testing and 

another biopsy is not always feasible. Blood-based testing is evolving as a useful 

prognostic and predictive tool and may have the potential to measure emerging 

resistance prior to detection of progression on conventional imaging. This 

educational program will: 

 

 

 

Review the unmet clinical needs across the continuum of care in nonsmall 

cell lung cancer (NSCLC) 

Assess genomic and proteomic technologies being utilized to measure 

blood-based biomarkers that are prognostic, predictive, and useful for 

detecting emerging resistance prior to conventional imaging 

Examine the analytic and clinical data associated with the current bloodbased 

tests that exist across the continuum care in NSCLC (both 

genomic and proteomic biomarkers) 

8


 

 

Introduce the challenges of tissue-based testing to predict response to 

immunotherapies 

Introduce early phase development of blood-based tests to predict 

response to immunotherapies 

© Biodesix, Inc. 2015. ALL RIGHTS RESERVED. 

Symposium supported by Genentech: The PD-L1 Pathway in Cancer Immune 

Evasion 

Speakers: Daniel Morgensztern, USA 

Room: 401 - 404 

07:00 - 08:00 MTE 01: Meet the Expert: Endpoints in Clinical Trials in Advanced NSCLC 

(Ticketed Session) 

Track: Treatment of Advanced Disease - NSCLC 

Speakers: Tony Mok, Hong Kong & Gideon Blumenthal, USA 

Room: 103 

07:00 - 08:00 MTE 02: Meet the Expert: Patients, Investigators and Pharmaceuticals 

Working Together to Accelerate Research and Access: The Lung Cancer Master 

Protocol (Lung-MAP) Clinical Trial (Ticketed Session) 

Track: Advocacy 

Speakers: Vassiliki Papadimitrakopoulou, USA & Kim Norris, USA 

Room: 105 

07:00 - 08:00 MTE 03: Meet the Expert: Squamous Cell Lung Cancer (Ticketed Session) 

Track: Biology, Pathology & Molecular Testing 

Speaker: Howard West, USA 

Room: 107 

07:00 - 08:00 MTE 04: Meet the Expert: Molecular Testing in Community Settings (Ticketed 

Session) 

Track: Community Practice 

Speaker: John Longshore, USA 

Room: 109 

07:00 - 08:00 MTE 05: Meet the Expert: Role of the Interventional Pulmonologist and 

Medical Pleuroscopy (Ticketed Session) 

Track: Treatment of Localized Disease - NSCLC 

Speaker: Pyng Lee, Singapore 

9


Room: 111 

07:00 - 08:00 MTE 06: Meet the Expert: Curative Radiotherapy for Local or Locoregional 

Disease (Ticketed Session) 

Track: Treatment of Locoregional Disease - NSCLC 

Speakers: Yasuhi Nagata, Japan & Joseph Salama, USA 

Room: 102 + 104 + 106 

07:00 - 08:00 MTE 07: Meet the Expert: Pharmacologic and Non-Pharmacologic 

Management of Dyspnea (Ticketed Session) 

Track: Palliative and Supportive Care 

Speaker: Alex Molasiotis, Hong Kong 

Room: 108 + 110 + 112 

07:00 - 08:00 MTE 08: Meet the Expert: Tobacco Control: What Do the Experts Do? (Ticketed 

Session) 

Track: Prevention & Tobacco Control 

Speakers: Emily Stone, Australia & Ellen Gritz, USA 

Room: 702 + 704 + 706 

07:00 - 08:00 MTE 09: Meet the Expert: Treatment of Advanced SCLC Including Second Line 


Track: Small Cell Lung Cancer 

Speakers: Taofeek Owonikoko, USA & Caicun Zhou, China 

Room: 708 + 710 + 712 

07:00 - 08:00 MTE 10: Meet the Expert: Subsolid Nodules: What the Clinicians Need to Know 

/ Clinical Workup of CT Detected Nodules (Ticketed Session) 

Track: Screening and Early Detection 

Room: 703 

 

 

Subsolid Nodules: What the Clinicians Need to Know – Kavita Garg, USA 

Clinical Workup of CT Detected Nodules – Reginald Munden, USA 

07:00 - 08:00 MTE 11: Meet the Expert: Mediastinal Tumors Including Thymic Tumors, 

Lymphoma, Germ-Cell Tumors: Biology, Diagnosis and Treatment (Ticketed 

Session) 

Track: Thymoma, Mesothelioma & other Thoracic Malignancies 

Speakers: Lawrence Einhorn, USA & Gregory Riely, USA & Enrico Ruffini, Italy 

Room: 201 + 203 

10


08:15 - 09:45 Plen 01: Plenary Session: Lung Cancer Prevention and Screening 

Track: Plenary 

Chairs: Harvey Pass, USA & Carolyn Dresler, USA 

Room: Plenary Hall (Bellco Theatre) 

 

 

 

Lung Cancer Screening - Christine Berg, USA 

Epidemiology of Lung Cancer/Smoking in the World - David Christiani, 

USA 

Smoking by Lung Cancer Patients: Clinical, Biologic and Behavioral 

Considerations - Graham Warren, USA 

09:45 - 10:45 Networking Break and Poster Session 1 

Room: Exhibit Hall (Hall B + C) 

Refreshments will be provided 

09:45 - 10:45 Press Conference 2 

Moderator: Dr. James Jett, Congress Co-Chair, Professor of Medicine at National 

Jewish Health in Denver, Colo. 

Room: 108 + 110 + 112 

 

 

 

 

 

 

Daily Theme: Lung Cancer Prevention & Screening - Dr. Claudia 

Henschke, Professor of Radiology and head of Lung and Cardiac 

Screening Program at Mount Sinai Medical Center, New York 

New Tobacco Declaration from IASLC - Dr. Kenneth Michael Cummings, 

Chair of Tobacco Control and Smoking Cessation Committee, IASLC 

Abstract – Impact of Time to Drug Approval on Potential Years of Life 

Lost: The Compelling Need for Improved Trial and Regulatory Efficiency - 

Dr. David Stewart, Head, Division of Medical Oncology, University of 

Ottawa/The Ottawa Hospital 

Abstract – Results From Phase III Trials of Anamorelin in Advanced Non- 

Small Cell Lung Cancer Patients with Cachexia: ROMANA 1 and 2 - Dr. 

Philip Bonomi, Professor, Rush University Medical Center – Medical 

Oncology, Chicago, Ill. 

Abstract – Bevacizumab 15mg/kg Plus Cisplatin-Pemetrexed (CP) vs CP 

in Malignant Pleural Mesothelioma (MPM): IFCT-GFPC-0701 MAPS 

Randomized Phase 3 Trial - Dr. Arnaud Scherpereel, Head of the 

Pulmonary and Thoracic Oncology Department and Professor at the 

University Hospital (CHU) of Lille, France 

Q & A 

10:00 - 10:30 Exhibit Showcase Session: Lilly Oncology Metastatic Non-Small Cell Lung 

Cancer (NSCLC) Promotional Presentation 

11


 

 

 

 

 

 

 

 

Phase 3, Randomized Trial (CheckMate 017) of Nivolumab (NIVO) vs 

Docetaxel in Advanced Squamous (SQ) Cell Non-Small Cell Lung Cancer 

(NSCLC) - Karen Reckamp, USA 

Safety and Efficacy of Nivolumab in an Ongoing Trial of a PD-L1+/- 

Patient Population with Metastatic Non-Small Cell Lung Cancer - Maen 

Hussein, USA 

Longer-Term Follow-Up of a Phase 2 Study (CheckMate 063) of 

Nivolumab in Patients with Advanced, Refractory Squamous Non-Small 

Cell Lung Cancer - Leora Horn, USA 

Discussant - Solange Peters, Switzerland 

Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed 

Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC) - 

Naiyer Rizvi, USA 

Evaluation of PD-L1 Expression in Metachronous Tumor Samples and 

FDG-PET as a Predictive Biomarker in Ph2 Study (FIR) of Atezolizumab 

(MPDL3280A) - Jamie Chaft, USA 

Atezolizumab (MPDL3280A) Combined with Platinum-Based 

Chemotherapy in Non-Small Cell Lung Cancer (NSCLC): A Phase Ib Safety 

and Efficacy Update - D. Ross Camidge, USA 

Discussant - Glenwood Goss, Canada 

10:45 - 12:15 Oral Session 03: New Kinase Targets 

Track: Treatment of Advanced Diseases - NSCLC 

Moderators: Fiona Blackhall, United Kingdom & Rosalyn Juergens, Canada 


 

 

 

 

 

 

 

 

Anlotinib as 3rd-Line Treatment for Refractory Advanced NSCLC: A 

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 

Trial - Baohui Han, China 

Is EGFR Exon20 Mutation a Prognostic/Predictive Biomarker in Our Lung 

Cancer Patients? - Deepa Joy Philip, India 

EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of 

Sensitivity to Afatinib or Neratinib but Not to Other EGFR-TKIs - 

Yoshihisa Kobayashi, Japan 

Discussant - Howard West, USA 

Clinical Outcomes with Pemetrexed-Based Systemic Therapy in RET- 

Rearranged Lung Cancers - Alexander Drilon, USA 

Activity of Crizotinib in MET Amplified NSCLC: Preliminary Results of the 

AcSé Trial - Denis Moro-Sibilot, France 

Response to MET Inhibitors in Stage IV Lung Adenocarcinoma Patients 

with Mutations That Cause MET Exon 14 Skipping - Paul Paik, USA 

Discussant - Ravi Salgia, USA 

10:45 - 12:15 Oral Session 04: Adjuvant Therapy for Early Stage Lung Cancer 


Moderators: Eric Vallieres, USA & Yuichiro Ohe, Japan 

13


Rooms: 205 + 207 

 

 

 

 

 

 

 

 

Final Results of Phase III Trial of Adjuvant Chemo?Immunotherapy in 

Lung Cancer - Hideki Kimura, Japan 

Research of Vascular Targeted Therapy in the Postoperative Adjuvant 

Chemotherapy for Lung Cancer - Zhiwei Chen, China 

Preliminary Results of the International Tailored Chemotherapy 

Adjuvant Trial: The ITACA Trial - Silvia Novello, Italy 

Discussant - Hossein Borghaei, USA 

Results Ph III Trial Customized Adjuvant CT after Resection of NSCLC 

with Lymph Node Metastases SCAT: A Spanish Lung Cancer Group Trial - 

Bartomeu Massuti, Spain 

Impact of demographic and health system factors on adjuvant 

chemotherapy use in stage II Non-small Cell Lung Carcinoma: A National 

Cancer Database analysis from 2000 to 2012 - Gaurav Goyal, USA 

Adjuvant Chemotherapy in Patients with Resected Non-Small-Cell-Lung 

Cancer Treated with Carboplatin and Oral Vinorelbine - SWITCH I Study - 

Vitezslav Kolek, Czech Republic 

Discussant - Giorgio Scagliotti, Italy 

10:45 - 12:15 Oral Session 05: Surgery 


Moderators: Paul Van Schil, Belgium & Feng-Ming (Spring) Kong, USA 

Rooms: 201 + 203 

 

 

 

 

 

 

 

 

Prognostic Value of 18F-FDG PET/CT in Surgical NSCLC: A Meta-Analysis 

- Ligang Xing, China 

Quality of Resection in Pathological N2 NSCLC in the Phase 3 Lung 

Adjuvant Radiotherapy Trial (Lung ART): An Important Factor - John 

Edwards, United Kingdom 

Transcervical Mediastinal and Hilar Lymphadenectomy (TCML) Provides 

Accurate Pre-Treatment Cancer Staging and Facilitates Resection - 

Robert Cameron, USA 

Discussant - Isabelle Opitz, Switzerland 

Trimodality Therapy in the Treatment of Stage IIIA Non-Small Cell Lung 

Cancer (NSCLC): A National Cancer Database Analysis - Madhusmita 

Behera, USA 

Long-Term Survival after Lobectomy for Locally Advanced NSCLC 

between Improved Video-Assisted Thoracoscopic Lobectomy and 

Thoracotomy - Kezhong Chen, China 

Mediastinal Lymphadenectomy Fulfilling NCCN Criteria May Improve 

the Outcome of Clinical N0-1 and Pathological N2 Non-Small Cell Lung 

Cancer - Nan Wu, China 

Discussant - Enrico Ruffini, Italy 

10:45 - 12:15 Oral Session 06: Next Generation Sequencing and Testing Implications 

14


Track: Biology, Pathology, and Molecular Testing 

Moderators: Gilberto De Lima Lopes, Brasil & Vincent Miller, USA 


Genomic Characterization of Large-Cell Neuroendocrine Lung Tumors - 

Lynnette Fernandez-Cuesta, France 

Targeted Deep Sequencing of EGFR/KRAS/ALK-Negative Lung 

Adenocarcinoma Reveals Potential Therapeutic Targets - Hye Ryun Kim, 

South Korea 

Genome-Wide Gene Copy Number Analysis by OncoScanTM FFPE Assay 

in 976 Resected NSCLC From LACE-Bio2 - Ming Tsao, Canada 

Discussant - Ramaswamy Govindan, USA 

Molecular Tumor Board (MTB) in Non-Small Cell Lung Cancers (NSCLC) 

to Optimize Targeted Therapies: 4 Years' Experience at Gustave Roussy - 

David Planchard, France 

Impact of Reflex EGFR/ALK Testing on Time-To-Treatment and 

Integration of Personalized Medicine in Advanced Non-Small Cell Lung 

Cancer Patients - Parneet Cheema, Canada 

An Integrated Cost-Effectiveness and Outcome Analysis Based on 

Multiplex Lung Cancer Genotyping in the Network Genomic Medicine - 

Anna Kostenko, Germany 

Discussant - Pan-Chyr Yang, Taiwan 

10:45 - 12:15 Oral Session 07: Lung Cancer Pathogenesis 


Moderators: Julien Sage, USA & Elisabeth Brambilla, France 

Rooms: 102 + 104 + 106 

 

 

 

 

 

 

 

 

Evaluation of Epigenetic Mechanisms of Pluripotency in Human 

Respiratory Epithelia - Vivek Shukla, USA 

Metabolic Reprogramming in the Airway Epithelium of Individuals at 

High Risk for Lung Cancer - S.M Jamshedur Rahman, USA 

MMP12 and LMO7 Are Key Genes Involved in the Early Pathogenesis of 

Squamous Cell Carcinoma of the Lung - Vitor Teixeira, United Kingdom 

Discussant - Mary Beth Beasley, USA 

Differential Tumorigenic Properties of Mesenchymal Cells From 

Neoplastic and Non-Neoplastic Human Lung in NSCLC - Federico Quaini, 

Italy 

Sox2 Cooperates with Lkb1 Loss to Promote Mouse Model of Squamous 

Cell Lung Cancer - Trudy Oliver, USA 

Evidence and Mechanism for the Transdifferentiation of Lung 

Adenocarcinoma to Squamous Cell Carcinoma - Xiangkun Han, China 

Discussant - Yasushi Yatabe, Japan 

10:45 - 12:15 Oral Session 08: Smoking Cessation, Tobacco Control and Lung Cancer 

Track: Prevention and Tobacco Control 

15


Moderators: Graham Warren, USA & Jacek Jassem, Poland 

Rooms: 601 + 603 

 

 

 

 

 

 

 

 

The History of Tobacco Litigation in the United States - Kenneth 

Cummings, USA 

Interest in Smoking Cessation Treatment among Patients in a 

Community-Based Multidisciplinary Thoracic Oncology Program - 

Kenneth Ward, USA 

Smoking Cessation Before the Initiation of Chemotherapy in Metastatic 

NSCLC: Impact on Overall Survival - Marie-Hélène Lelièvre, Canada 

Discussant - Jamie Ostroff, USA 

Impact of an Inpatient Tobacco Cessation Service - Kenneth Cummings, 

USA 

Introducing Smoking Cessation Across Ontario's Cancer Treatment 

System: Early Successes and Continuing Challenges - William K Evans, 

Canada 

Primary Prevention of Lung Cancer in Poland - Successes and Challenges 

- Jacek Jassem, Poland 

Discussant - Emily Stone, Australia 

10:45 - 12:15 Oral Session 09: CT Screening - New Data and Risk Assessment 


Moderators: James Mulshine, USA & John Field, United Kingdom 


 

 

 

 

 

 

 

 

Discerning Malignant and Benign New Nodules at Incidence Rounds of 

CT Lung Cancer Screening: The Role of Volume and Predicted Volume 

Doubling Time - Rozemarijn Vliegenthart, Netherlands 

Results of the Fourth Screening Round of the NELSON Lung Cancer 

Screening Study - Uraujh Yousaf-Khan, Netherlands 

The Danish Lung Cancer Screening Trial: Results 5 Years after Last CT 

Screening - Jesper Pedersen, Denmark 

Discussant - Nir Peled, Israel 

Lung-RADS versus the McWilliams Nodule Malignancy Score for Risk 

Prediction: Evaluation on the Danish Lung Cancer Screening Trial - Sarah 

Van Riel, Netherlands 

The Cancer Risk Management Model: A Tool to Inform Canadian 

Policymakers Implementing Low-Dose CT Screening for Lung Cancer - 

William K Evans, Canada 

Economic Evidence for the Use of Risk-Selection and Risk-Stratification 

for Lung Cancer Screening Programs - Sonya Cressman*, Canada 

Discussant - Stephen Malkoski, USA 

10:45 - 12:15 Oral Session 10: SCLC 


Moderators: Corinne Faivre-Finn, United Kingdom & Primo Lara, USA 

16


Rooms: 605 + 607 

 

 

 

 

 

 

 

 

A DLL3-Targeted ADC, Rovalpituzumab Tesirine, Demonstrates 

Substantial Activity in a Phase I Study in Relapsed and Refractory SCLC - 

Charles Rudin, USA 

A Prospective Randomized Phase III Study of Continuum Chemotherapy 

versus Chemo-Radiotherapy in ES-SCLC in Asian Indian - Satya Narayan, 

India 

Which Patients with ES-SCLC Should Receive Thoracic Radiotherapy 

(TRT) Routinely? - Berend Slotman, Netherlands 

Pembrolizumab for ED SCLC: Efficacy and Relationship with PD-L1 

Expression - Patrick Ott, USA 

Discussant – Primo Lara, USA 

Long-Term Survival after Surgery for Pathologic N1 and N2 Small Cell 

Lung Cancer: A Comparison with Nonoperative Management - Chi-Fu 

Yang, USA 

Clinical and Molecular Profiling of Surgically Resected Small Cell Lung 

Cancer - Kei Takamura, Japan 

Discussant - David Ball, Australia 

10:45 - 12:15 Oral Session 11: Clinical Trials 1 

Track: Thymoma, Mesothelioma and Other Thoracic Malignancies 

Moderators: Anna Nowak, Australia & Frank Detterbeck, USA 

Rooms: 702 + 704 + 706 

 

 

 

 

 

 

 

 

Phase I Study of Anti-Mesothelin Antibody Drug Conjugate Anetumab 

Ravtansine - Raffit Hassan, USA 

Single-Agent Pembrolizumab for Patients with Malignant Pleural 

Mesothelioma (MPM) - Evan Alley, USA 

Bevacizumab 15mg/kg Plus Cisplatin-Pemetrexed (CP) vs CP in 

Malignant Pleural Mesothelioma (MPM): IFCT-GFPC-0701 MAPS 

Randomized Phase 3 Trial - Arnaud Scherpereel, France 

Discussant - Dean Fennell, United Kingdom 

Phase II Trial of Single Agent Amrubicin in Patients with Previously 

Treated Advanced Thymic Malignancies - Heather Wakelee, USA 

A Prospective Phase II Study of Cisplatin and Cremorphor EL-Free 

Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial 

Tumors:: Can 18F-FDG PET/CT play a role? - Hae Su Kim, South Korea 

Computed Tomography (CT) Characteristics Associated with the 

Proposed IASLC/ITMIG TNM Pathologic Staging System for Thymoma - 

Sukhmani Padda, USA 

Discussant - Nicolas Girard, France 

10:45 - 12:15 Oral Session 12: Quality of Life and Trials 


Moderators: Evi Bachrach Makovsky, USA & Christie Malnati, USA 

17


Rooms: 708 + 710 + 712 

 

 

 

 

 

 

 

 

Priority of Daily Life v's Medical Care Challenges for Lung Cancer 

Patients and Carers - Aoife McNamara, Ireland 

The PACE Continuous Innovation IndicatorsTM: A New Tool to 

Objectively Measure Progress and Identify Unmet Needs in Lung Cancer 

Treatments - Silvia Paddock, USA 

The Predictors and Effects of Explicit and Implicit Attitudes Against Lung 

Cancer (LC) - Tsung-wei Ma, USA 

Discussant - Michael Weitz, USA 

Impact of Time to Drug Approval on Potential Years of Life Lost: The 

Compelling Need for Improved Trial and Regulatory Efficiency - David 

Stewart, Canada 

Trial Eligibility of NSCLC Patients Receiving Proton Therapy: Are 

Cooperative Group Trials Being Designed for the Right Patients? - 

Megan Dunn, USA 

Twitter: Is There an Opportunity to Improve Participation in Lung Cancer 

Clinical Trials? - Mina Sedrak, USA 

Discussant - David Sturges, USA 

10:45 - 12:15 Mini Oral 01: Pathology 


Moderators: Wilbur Franklin, USA & Andrew Nicholson, United Kingdom 

Room: Mile High Ballroom 2c - 3c 

 

 

 

 

 

 

 

 

 

Immunohistochemical Distinction between Primary Lung Squamous Cell 

Carcinoma and Pulmonary Metastasis of Head and Neck Squamous Cell 

Carcinoma - Junji Ichinose, Japan 

Is It Possible to Distinguish between Second Primary vs Metastasis in 

Resectable Synchronous Nodules with the Same Histotype of Lung 

Cancer? - Giulia Luciano, United Kingdom 

Pathology-Imaging Agreement in Distinguishing Separate Primary 

Tumours and Intrapulmonary Metastasis in Staging of Multiple Lung 

Cancers - Patrizia Viola, United Kingdom 

Discussant - Natasha Rekhtman, USA 

Local Diagnostic Practices for Advanced Non-Small-Cell Lung Cancer in 

Europe and Japan: ASSESS Study - Nicola Normanno, Italy 

Pathological Second-Predominant Component Predicts Recurrence in 

Lung Adenocarcinoma - Masaoki Ito, Japan 

Comparison of Grading Systems Based on Histologic Patterns and 

Mitotic Activity to Predict Recurrence in Stage I Lung Adenocarcinoma 

(ADC) - Kay See Tan, USA 

Survival Differences of Adenocarcinoma Lung Tumors with Squamous 

Cell Carcinoma or Neuroendocrine Profiles by Gene Expression 

Subtyping - Hawazin Faruki, USA 

Discussant - Erik Thunnissen, Netherlands 

18


Analysis of the Status of Lymphocyte Infiltration in Patients with NSCLC - 

Martin Richardet, Argentina 

Transcriptome Sequencing of Tumor vs. Surrounding Non-Malignant 

Lung Tissue in Non-Small Cell Lung Cancer - Dirk De Ruysscher, Belgium 

Implementation of a Molecular Tumor Board: The Impact on Treatment 

Decisions for NSCLC Patients Evaluated at Dartmouth-Hitchcock in One 

Year - Laura Tafe, USA 

Biologically Driven Sub-Classification of Early Lung Adenocarcinomas - 

John Le Quesne, United Kingdom 

Discussant - Katerina Politi, USA 

10:45 - 12:15 Mini Oral 02: Immunotherapy 


Moderators: Patrick Forde,USA & Scott Antonia, USA 

Room: Four Seasons Ballroom F3 + F4 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pulmonary Large Cell Carcinoma and Solid Adenocarcinoma Are Highly 

Mutated with Frequent Expression of PDL1 - Lynette Sholl, USA 

Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung 

Adenocarcinomas and Nodal Metastases - Hironori Uruga, USA 

Overexpression of CD47, Decrease of Apoptosis and Phagocytosis of 

Neutrophils in Advanced Non-Small Cell Lung Cancer Patients - Lourdes 

Barrera, Mexico 

Sequential Assessment of DNA Damage Response and PD-L1 Expression 

in Circulating Tumor Cells of Lung Cancer Patients during Radiotherapy - 

Steven Lin, USA 

Discussant - David Carbone, USA 

Humanized Immuno-Mouse for Study of Anti-PD-1 Therapy in KRAS- 

Mutated Lung Cancer Patient Derived Xenotransplant (PDX) - James 

Keck, USA 

Preclinical Rationale for a Phase I/II Study of Pembrolizumab (P) and 

Vorinostat (V) in Immune Therapy Naïve and Pretreated Stage IV NSCLC 

- Nishan Tchekmedyian, USA 

Bidirectional Cross-Talk between CD14+ Monocytes and Human Lung 

Cancer Cell Lines Results in Different Phenotypic and Functional 

Outcomes - Erin Schenk, USA 

ERK Activation Mediates Increased PD-L1 Expression in KRAS Mutated 

Premalignant Human Bronchial Epithelial Cells - Jay Lee, USA 

Discussant - Ignacio Wistuba, USA 

Immunological Markers Predict the Prognosis of Patients with 

Squamous Non-Small Cell Lung Cancer - Long Jiang, China 

Distribution of Immune Markers and Their Association with Overall 

Survival and Time to Progression in Non-Small-Cell Lung Cancer (NSCLC) 

- Andrew Kuykendall, USA 

Immune Related Gene Signature Reveal Potential Role for Leukocyte- 

Associated Immunoglobin-Like Receptor 2 (LAIR2) in Lung Cancer 

Regulation - Dalam Ly, Canada 

19


 

Discussant - Vassiliki Papadimitrakopoulou, USA 

12:30 - 14:00 Symposium supported by Lilly: Beyond The Guidelines - Management of 

Patients with Non-Small Cell Lung Cancer without Targetable Tumor 

Mutations 


 

Webpage: www.researchtopractice.com/Meetings/IASLC2015/NSCLC 

14:15 - 15:45 MS 01: Mini Symposium: How to Treat Multiple GGO’s 


Chairs: Jessica Donington, USA & Masahiro Tsuboi, Japan 

Rooms: 102 + 104 + 106 

What is the Appropriate Diagnostic Technique in the Setting of Multiple 

GGO’s? - Charles Powell, USA 

What is the Role of Surgical Resection in the Setting of Multiple GGO’s? 

- Raja Flores, USA 

Is There a Role for Targeted Therapy or Conventional Chemotherapy in 

Patients with Multiple GGO’s? - Benjamin Levy, USA 

The Pathologic Classification of GGO’s - Clinical Pathologic Correlation - 

Erik Thunnissen, Netherlands 

14:15 - 15:45 MS 02: Mini Symposium: Are Non-Tissue Biomarkers Ready for the Clinic? 


Chairs: Andreas-Claudius Hoffmann, Germany & Luis Montuenga, Spain 

Rooms: 401 - 404 

 

 

 

 

Free Circulating Tumor DNA - Philip Mack, USA 

Circulating Tumor Cells - Tilak Sundaresan, USA 

Blood-Based Proteomics Strategies for the Early Detection of Lung 

Cancer – Ruben Pío, Spain 

Exhaled Breath - Nir Peled, Israel 

14:15 - 15:45 MS 03: Mini Symposium: Is Tumor Angiogenesis Still a Viable Target in 

Advanced NSCLC? 


Chairs: Sanjay Popat, United Kingdom & Qinghua Zhou, China 

Rooms: 605 + 607 

 

 

Current Understanding of the Biology - John Heymach, USA 

Anti-Angiogenic Therapy: Current and Future Agents - Suresh 

Ramalingam, USA 

20


 

 

Where are we with Defining Potential Biomarkers - Geoffrey Liu, 

Canada 

An Update on Clinical Trials: Is Tumor Angiogenesis Still a Viable Target 

in Advanced NSCLC? - Heather Wakelee, USA 

14:15 - 15:45 MS 04: Mini Symposium: Harnessing the Full Potential of the Immune System 


Chairs: Charles Butts, Canada & Patrick Forde, USA 


 

 

 

 

PD1/PDL1 Studies - Roy Herbst, USA 

Other Immune Inhibitors - Naiyer Rizvi, USA 

Vaccines - Johan Vansteenkiste, Belgium 

Microenvironment as a Target - Steven Albelda, USA 

14:15 - 15:45 MS 05: Mini Symposium: Tumor Heterogeneity 


Chairs: Sanja Dacic, USA & Andrew Nicholson, United Kingdom 

Room: Mile High Ballroom 1a – 1f 

 

 

 

 

Overview of Tumor Heterogeneity - Charles Swanton, United Kingdom 

How Does Tumor Heterogeneity Affect Molecular Testing on Biopsy 

Samples - Diagnostic vs. Rebiopsy (Resistance) - Keith Kerr, United 

Kingdom 

Genomic Evolution and Tumor Heterogeneity - David Sidransky, USA 

Heterogeneity and Drug Resistance - Solange Peters, Switzerland 

14:15 - 15:45 MS 06: Mini Symposium: Regulation of Tobacco Products 


Chairs: Edgardo Santos, USA & Nise Yamaguchi, Brazil 

Rooms: 201 + 203 

 

 

 

 

Global Effects of Smoking, of Quitting, and of Taxing Tobacco - Luk 

Joossens, Belgium 

The Framework Convention on Tobacco Control - Geoffrey Fong, 

Canada 

FDA Regulation of Tobacco Products in the US - Mitch Zeller, USA 

The Role of Litigation in Controlling Tobacco Use - Richard Daynard, 

USA 

14:15 - 15:45 MS 07: Mini Symposium: SCLC Biology & Models 

Track: Small Cell Lung Cancer / Biology, Pathology & Molecular Testing 

Chairs: Desmond Carney, Ireland & Charles Rudin, USA 

21


Room: Mile High Ballroom 4a – 4f 

PDX Models - Charles Rudin, USA 

GEM Models (p53/Rb) - Kate Sutherland, Australia 

Pre-Clinical Mouse Models of SCLC to Identify and Validate New 

Therapeutic Targets - Julien Sage, USA 

From GEMMs to ROCKs – An Assessment of In Vitro Models for the 

Study of SCLC - Adi Gazdar, USA 

Circulating Tumour Cells - Fiona Blackhall, United Kingdom 

14:15 - 15:45 MS 08: Mini Symposium: BAP1 Cancer Syndrome and Mesothelioma 


Chairs: Lee Krug, USA & Nico Van Zandwijk, Australia 

Rooms: 702 + 704 + 706 

 

 

 

 

Mesothelioma and BAP1 Germline Mutations - Michele Carbone, USA 

BAP1 and Ubiquitination - El Bachir Affar, Canada 

Screening for BAP1 in Danish Families - Karin Wadt, Denmark 

BAP1: Lessons from Renal Cell Carcinoma - James Brugarolas, USA 

14:15 - 15:45 MS 09: Mini Symposium: Worldwide Perspective/Review of Limitations, 

Resources, Programs and Accomplishments of Supportive Care and Palliative 

Care Multidisciplinary Teams, by Continent 


Chairs: Roberto Ivan Lopez, Panama & Ana Oton, USA 

Rooms: 108 + 110 + 112 

 

 

 

 

 

 

 

 

 

 

Part 1: The Palliative Care Multidisciplinary Team and Worldwide 

Perspective 

Nurse’s Perspective - Teresa Trabert, USA 

Doctor’s Perspective – Hitesh Bhanabhai, Canada 

Radiation Oncologist’s Perspective - Jeffrey Bradley, USA 

Patient and Caregiver’s Perspective - Regina Fink, USA 

Part 2: Review of Limitations, Resources, Programs and 

Accomplishments of Supportive Care and Palliative Care 

Multidisciplinary Teams, by Continent 

Latin America - Eduardo Arnoldo Richardet, Argentina 

Africa - Moawia Elhassan, Sudan 

Asia/Oceania - Craig Underhill, Australia 

Supportive Care and Palliative Care in Europe - Jorn Herrstedt, Denmark 

14:15 - 15:45 MS 10: Mini Symposium: Management of Screening Detected Lung Cancer 

Track: Treatment of Localized Disease - NSCLC / Screening and Early Detection 

Chairs: Peter Goldstraw, United Kingdom, Norihiko Ikeda, Japan, Bernard Park, 

USA & Luis Raez, USA 

22



 

 

 

 

 

 

 

Epidemiology of Lung Cancer and Smoking - Ping Yang, USA 

Positive Lung Cancer Screens - Which Ones are Lung Cancer? - Martin 

Tammemägi, Canada 

What is the Ideal Method of Diagnosis for Screening Detected Lung 

Nodules? - Doug Minnich, USA 

When to Intervene on Screening Detected Lung Nodules - Giulia 

Veronesi, Italy 

Rationale for Sublobar Resection for Early Cancer - Hisao Asamura, 

Japan 

Is There a Role for SBRT in Screening Detected Non-Diagnosed Lung 

Nodules? - David Palma, Canada 

Biomarkers: Current Status and Future Direction - Rob Young, New 

Zealand 

14:15 - 15:45 ED 01: Education Session: Update in Radiation Oncology 


Chairs: Walter Curran, USA & Paul van Houtte, Belgium 

Rooms: 205 + 207 

 

 

 

 

Current Status of Proton and Heavy Particle Therapy - Hak Choy, USA 

Optimal Dose and Fractionation - James Urbanic, USA 

Post-Operative Radiotherapy for Stage III Disease - Francoise Mornex, 

France 

Evolving Role of Radiation for Oligometastases - Benjamin Movsas, USA 

14:15 - 15:45 ED 02: Education Session: Molecular Testing Around the World (Genomics in 

Clinic (Timelines/Bioinformatics), Testing Platforms & Algorithms (NGS, 

Targeted Panels, FISH, IHC), Cost Considerations, Strategies for Identifying 

Rare Genomic Subsets in Clinical Trials) 


Chairs: Marc Ladanyi, USA & Gilberto Lopes, Brazil 


 

 

 

 

North America - Vincent Miller, USA 

Asia - Jin-Haeng Chung, South Korea 

Europe – Céline Mascaux, Belgium 

Central/South America - Lilian (Mercedes) Dalurzo, Argentina 

14:15 - 15:45 ED 03: Education Session: Global Lung Cancer Coalition – Data-Driven Lung 

Cancer Advocacy 


Chairs: Maureen Rigney, USA & Joan Schiller, USA 

Room: 703 

23


Global Lung Cancer E-Atlas - How Can This be Ssed as a Tool to Advocate 

for Change? - Sarah Winstone, United Kingdom 

Bibliometric Research on Published Lung Cancer Research - What are 

the Implications for Policy Work? - Richard Sullivan, United Kingdom 

The Value of National Lung Cancer Audit Data - The UK Experience - 

Jesme Fox, United Kingdom 

Advocating for Tobacco Control - The Australia Experience - Matthew 

Peters, Australia 

14:15 - 15:45 ED 04: Education Session: How to Set Up a Multidisciplinary Lung Cancer 

Program within a Community Care Environment and Provide Everyone with 

the Best Care for Lung Cancer 


Chairs: Juan Manuel Luna, Guatemala & Samir Witta, USA 


 

 

 

 

 

 

How can Multi-Disciplinary Care be Executed at the Private Practice 

Level? - Eric Edell, USA 

How can we Strengthen MD Care in Large Hospital Systems? - Kathryn 

Mileham, USA 

Treating Diverse Communities - Laurie Carr, USA 

Differences in Rural/Urban Care - Craig Reynolds, USA 

The Use of Pathways to Guide Consistency - Edward Kim, USA 

Evaluating Quality of Care Outcomes from Screening to Treatment in 

Community Based Settings - Richard Booton, United Kingdom 

14:15 - 15:45 ED 05: Education Session: Case Presentations (3 lung cancer and 1 

mesothelioma) discussed in round table format 

Track: Nursing and Allied Professionals 

Chairs: Mary Duffy, Australia & Mary Hesdorffer, USA 

Rooms: 708 + 710 + 712 

 

 

 

 

 

 

Nursing - Patricia Palmer, USA 

Respiratory Therapy - Larry Di Fabrizio, USA 

Approach to Offering Remote Support to Mesothelioma Patients: The 

Mesothelioma Survivor Project – Gleneara Bates, USA 

Physician Assistant - Heather Grillo, USA 

PharmD - Ellen McGrath, USA 

Nurse Practitioner - Michelle Turner, USA 

14:15 - 15:45 Pro Con PC 01: Surgery vs. SBRT in Operable NSCLC 

Track: Treatment of Localized Disease - NSCLC / Treatment of Locoregional 

Disease - NSCLC 

Chairs: David Harpole, USA & Pan-Chyr Yang, Taiwan 

24


Rooms: 601 + 603 

SBRT - Suresh Senan, Netherlands 

Surgery - Paul Van Schil, Belgium 

Pro Con PC 01: Pro vs Con: SBRT for Non-Biopsied Lung Nodules 

Track: Treatment of Localized Disease - NSCLC / Treatment of Locoregional 

Disease - NSCLC 

Chairs: Philip Bonomi, USA & Antoinette Wozniak, USA 

Rooms: 601 + 603 

 

 

Pro - Kenneth Rosenzweig, USA 

Con - Robert Timmerman, USA 

15:45 – 16:45 Networking Break and Poster Session 1 


16:00 – 16:30 Exhibit Showcase Session: Lilly: Challenges with Squamous Non-Small Cell 

Lung Cancer 

Room: Exhibit Showcase Theater in the Exhibit Hall (Halls B + C) 

16:45 - 18:15 Advocacy in Action 

Room: 103 

Advocacy in Action (AIA) is Vital Options International’s signature platform for 

bringing together a cross-section of cancer advocates, patients, and healthcare 

professionals in settings across the globe to address key issues in cancer and the 

realities of those facing, fighting, and surviving cancer. At the 2015 World 

Conference on Lung Cancer AIA will be joining forces with IASLC and lung cancer 

advocates from around the globe to discuss: 

 

 

Lung Cancer Screening Worldwide 

Access to Care: What Are the Biggest Challenges for Lung Cancer 

Patients? 

16:45 - 18:15 Oral Session 13: Immunotherapy Biomarkers 


Moderators: Dong-Wan Kim, South Korea & Dominique Grunenwald, France 


 

PD-L1 Expression in Lung Adenocarcinomas Correlates with KRAS 

Mutations and Th1/Cytotoxic T Lymphocyte Microenvironment - Mari 

Mino-Kenudson, USA 

25


 

 

 

 

 

 

 

Characterization of PD-L1 Expression Related to Unique Genes in NSCLC 

Tissue Samples - Edward Garon, USA 

Spatiotemporal Effects on Programmed Death Ligand 1 (PD-L1) 

Expression and Immunophenotype of Non-Small Cell Lung Cancer 

(NSCLC) - Marcin Kowanetz, USA 

Discussant - Scott Gettinger, USA 

Predictive Biomarker Testing for Programmed Cell Death 1 Inhibition in 

Non-Small Cell Lung Cancer - Brandon Sheffield, Canada 

PDL-1 Expression in NSCLC: Analysis of a Large Early Stage Cohort; And 

Concordance of Expression in Primary, Nodes and Metastasis - Paul 

Mitchell, Australia 

EMT Is Associated with an Inflammatory Tumor Microenvironment with 

Elevation of Immune Checkpoints and Suppressive Cytokines in Lung 

Cancer - Yanyan Lou, USA 

Discussant - David Rimm, USA 

16:45 - 18:15 Oral Session 14: Biology 2 


Moderators: Takashi Nakano, Japan & Paul Baas, Netherlands 

Rooms: 702 + 704 + 706 

 

 

 

 

 

 

 

 

Early Contrast Enhancement as a Non-Invasive Objective Biomarker of 

Pleural Malignancy - Selina Tsim, United Kingdom 

Clinical Significance of Soluble CD26 in Malignant Pleural Mesothelioma 

- Nobukazu Fujimoto, Japan 

Integrin Linked Kinase Pathway: A Potential Driver of Tumorigenesis of 

Malignant Pleural Mesothelioma - Assunta De Rienzo, USA 

Discussant - David Schrump, USA 

Intracavitary Cisplatin-Fibrin After Resection of Malignant Pleural 

Mesothelioma - Isabelle Opitz, Switzerland 

MesobanK - an International Mesothelioma Tissue Bioresource - Now 

Open for Tissue Requests - Robert Rintoul, United Kingdom 

Preclinical Investigation of the Therapeutic Potential of Nintedanib in 

Malignant Pleural Mesothelioma - Viktoria Laszlo, Austria 

Discussant - Hedy Lee Kindler, USA 

16:45 - 18:15 Oral Session 15: Outcome Management in Lung Cancer Patients 


Moderators: Kahren White, USA & Molly Freeman, USA 

Rooms: 102 + 104 + 106 

Changes in Symptom Occurrence Rates from before through 12 Months 

following Lung Cancer Surgery - Trine Oksholm, Norway 

Identification and Management of Unique Immune Mediated Toxicities - 

Marianne Davies, USA 

26


 

 

 

 

 

 

Application of Ultrasound-Guided Femoral Venous Catheters Inserted at 

Various Sites in Patients with Superior Vena Cava Obstruction - Zhang 

Hui, China 

Discussant - Beth Sandy, USA 

Using Your Voice (UYV) - How to Use Your Nursing Voice at the Multi- 

Disciplinary Team (MDT) Meeting - Lavinia Magee, United Kingdom 

A Prospective Audit on Smoking Cessation and Lung Cancer Nurse 

Specialist Intervention within a Thoracic Oncology Service - Lavinia 

Magee, United Kingdom 

I Am Dying of Mesothelioma - Carol Davies, United Kingdom 

Discussant - Mary Duffy, Australia 

16:45 - 18:15 Mini Oral 03: PD1 Axis Inhibition and EGFR 


Moderators: Leena Gandhi, USA & Yuichiro Ohe, Japan 

Room: Four Seasons Ballrom F1 + F2 

 

 

 

 

 

 

 

 

 

 

 

Prior TKI Therapy in NSCLC EGFR Mutant Patients Associates with Lack 

of Response to Anti-PD-1 Treatment - Jonathan W. Goldman, USA 

PD-L1 Displays a Funtional Effect in the Acquired Chemoresistance in 

Lung Cancer - Panpan Zhang, China 

Pembrolizumab 2 mg/kg Q3W for Previously Treated, PD-L1?Positive 

Advanced NSCLC - Øystein Fløtten, Norway 

Discussant - Julie Brahmer, USA 

Efficacy of Pembrolizumab in Key Subgroups of Patients with Advanced 

NSCLC - Matthew Hellmann, USA 

Phase II Studies of Nivolumab in Patients with Advanced Squamous (SQ) 

or Non-Squamous (NSQ) Non-Small-Cell Lung Cancer (NSCLC) - Kazuhiko 

Nakagawa, Japan 

Clinical Attributes of Lung Cancer in US Community Oncology Practice: 

Implications for Immunotherapy - Praveen Reddy, USA 

Discussant - Jhanelle Gray, USA 

Role of T790M Mutation in EGFR-TKI Rechallenge for Patients with 

EGFR-Mutant Advanced Non-Small Cell Lung Cancer - Qiu -Yi Zhang, 

China 

Rociletinib in NSCLC Patients with Negative Central Testing for T790M in 

TIGER-X - Heather Wakelee, USA 

Discussant - Christian Rolfo, Belgium 

16:45 - 18:15 Mini Oral 04: Clinical Care of Lung Cancer 


Moderators: Laurie Gaspar, USA & Virginie Westeel, France 


 

Years of Life Lost and Lifetime Earnings Lost in Metastatic Lung Cancer: 

Potential Societal Benefits of Improved Survival by Age and Histology - 

Mark Danese, USA 

27


 

 

 

 

 

 

 

 

 

 

 

 

 

 

Value of Innovation in Systemic Therapy for US Patients with 

Advanced/Metastatic NSCLC - Jonas Nilsson, Sweden 

Real-World Patterns of Access to Cancer Specialist Care Among Patients 

With Lung Cancer in the United States: A Claims Database Analysis - 

Hossein Borghaei, USA 

Economic Burden of Lung Cancer Patients Treated in Clinical Trials: 

Experience from a Comprehensive Cancer Center in Germany - Florian 

Kron, Germany 

Discussant - Natasha Leighl, Canada 

During-Treatment PET Metabolic Tumor Volume (MTV) Instead of FDG 

Activity Is Predictive of Survival in Patients with Non-Small Cell Lung 

Cancer - Feng-Ming (Spring) Kong, USA 

Changes in Skeletal Muscle Index and Body Mass Are Prognostic Factors 

in First Line Stage IV Non-Small Cell Lung Cancer (NCSCL) Patients - Mary 

Fidler, USA 

Malignant Pleural Effusions Are Predictive of Peritoneal Carcinomatosis 

in Patients with Advanced EGFR Positive Non-Small Cell Lung Cancer - 

Tejas Patil, USA 

The Impact of Next-Generation Sequencing on Clinical Decisions in Lung 

Cancer - Anna Belilovski Rozenblum, Israel 

Discussant - Karen Reckamp, USA 

Incidence of Brain Metastasis in Non-Small Cell Lung Cancer Over Eleven 

Years at a Single Canadian Institution - Adrijana D'Silva, Canada 

Systematic Review of Brain Metastases in Non-Small Cell Lung Cancer 

(NSCLC) in the United States, European Union, and Japan - D. Christian 

Fenske, USA 

Survival Analysis of 51 Leptomeningeal Metastatic Non Small Cell Lung 

Cancer Patients Treated with Whole Brain Radiotherapy - Erkan Topkan, 

Turkey 

Comparative Survival in Patients with Brain Metastases from Non-Small 

Cell Lung Cancer Treated before and after Implementation of 

Radiosurgery - Anand Swaminath, Canada 

Discussant - Sue Yom, USA 

16:45 - 18:15 Mini Oral 05: EGFR Mutant Lung Cancer 1 


Moderator: Yasushi Yatabe, Japan & Roman Perez-Soler, USA 


A Progression Free Survival Score for EGFR Mutant Non-Small Cell Lung 

Cancer Patients Treat with First Line EGFR Tyrosine Kinase Inhibitors - 

Yu-Mu Chen, Taiwan 

Impact of ABCG2 Polymorphisms on the Clinical Outcome of TKIs 

Therapy in Chinese Advanced Non-Small-Cell Lung Cancer Patients - 

Xueqin Chen, China 

P53 Disruptive Mutation Is a Negative Predictive Factor in EGFR M+ 

NSCLC Treated with TKI - Frank Griesinger, Germany 

28


 

 

 

 

 

 

 

 

 

 

 

 

Survival Outcome Assessed According to Tumor Burden & Progression 

Patterns in Patients with EGFR Mutant NSCLC Undergoing EGFR-TKIs - 

Yoon Ki Cha, South Korea 

Discussant - Federico Cappuzzo, Italy 

Continuation of Epidermal Growth Factor Receptor Tyrosine Kinase 

Inhibitor Treatment Prolongs Disease Control in Non-Small-Cell Lung 

Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors - Qi 

Chen, China 

A Phase Ib/II Study of Afainib plus Nimotuzumab in Non-Small Cell Lung 

Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib - Ji 

Yun Lee, South Korea 

Circulating Tumor Cells and Evaluation of Targeted Therapy Effect in 

EGFR Mutation/ALK Translocation Metastatic Non-Small Cell Lung 

Cancer - chunxia Su, China 

Comparison of the Efficacy of Dacomitinib v Erlotinib for NSCLC Pts with 

Del 19/L858R - Suresh Ramalingam, USA 

Discussant - Renato Martins, USA 

EGFR-TKI Alone or with Concomitant Radiotherapy for Brain Metastases 

in Lung Adenocarcinoma Patients with EGFR Gene Mutations - 

Yongshun Chen, China 

Exon 19 Deletion Prolongs Survival in Brain Metastases from Non-Small 

Cell Lung Cancer - Hongwei Li, China 

Erlotinib Combined with Chemotherapy versus Erlotinib Alone Treating 

Advanced Lung Adenocarcinoma with Brain Metastases (NCT01578668) 

- Haihong Yang, China 

Treatment of EGFR/ALK-Driven Non-Small Cell Lung Cancer (NSCLC) 

Brain Metastases: Impact of First-Line Whole Brain Radiotherapy on 

Outcome - Mark Doherty, Canada 

Discussant - Benjamin Solomon, Australia 

16:45 - 18:15 Mini Oral 06: Quality/Prognosis/Survival 


Moderators: Robert Meguid, USA & Junji Yoshida, Japan 

Rooms: 605 + 607 

 

 

 

 

 

Prognostic Impact of Visceral Pleural Invasion and Its Degrees in Non- 

Small Cell Lung Cancer: A SEER Database Analysis - Lilan Zhao, China 

T1a Lung Adenocarcinomas: Presence of Spread of Tumor through 

Alveolar Spaces (STAS), Micropapillary and Solid Patterns Determines 

Outcomes - Kyuichi Kadota, Japan 

Improved Survival in Patients with Stage I-II NSCLC Treated with Surgery 

or Radiotherapy in the Department of Veterans Affairs - Joseph Salama, 

USA 

Impact of Attainment of the American College of Surgeons Commission 

on Cancer Quality Measure on Patient Survival After Lung Cancer 

Resection - Xinhua Yu, USA 

Discussant - David Harpole, USA 

29


Early-Stage Lung Cancer Treatment and Survival: Impact of Race - 

Michael Kelley, USA 

High Incidence of PD-L1 Expression in Surgically Resected Pulmonary 

Lymphoepithelioma-Like Carcinoma Is Linked to Prognosis - Yunpeng 

Yang, China 

Recognition Of "Aggressive" Nodal Metastatic Behavior In "Indolent" 

Ground Glass Opacity Lesions - Junyan Zha, China 

Aerogeneous Spread Is a Predictive Factor of Recurrence in Stage I Lung 

Adenocarcinoma - Satoshi Shiono, Japan 

Discussant - Odd Terje Brustugun, Norway 

The Influence of Body Mass Index on Overall Survival following Surgical 

Resection of Non-Small Cell Lung Cancer - Kathryn Gold, USA 

Prognostic Impact of Cancer-involved Lymph Node Ratio in Resected 

NSCLC Differ between 'N1' or 'N2' Disease - Wenhua Liang, China 

Multiple Lung Cancers: Is Their Survival Better or Worse Then Other 

Lung Cancers? - Jarushka Naidoo, USA 

The Impact of Serum EGFR Levels on Survival of Resected Patients with 

Non-Small Cell Lung Cancer - Elvin Hekimoglu, Turkey 

Discussant - Gavin Wright, Australia 

16:45 - 18:15 Mini Oral 07: ChemoRT and Translational Science 


Moderators: David Raben, USA & Brian Kavanagh, USA 

Rooms: 201 + 203 

 

 

 

 

 

 

 

 

A Randomized Phase II Study of S-1 and Cisplatin vs Vinorelbine and 

Cisplatin with Concurrent Radiotherapy for Locally Advanced NSCLC: 

WJOG5008L - Junichi Shimizu, Japan 

Chemoradiotherapy versus Radiotherapy Alone in Elderly Patients with 

Stage III Non-Small Cell Lung Cancer: A Systematic Review - David Dawe, 

Canada 

The NARLAL2 Phase III Trial: Heterogeneous FDG-Guided Dose 

Escalation of Advanced NSCLC. A Clinical Trial by the Danish Lung Cancer 

Group - Tine Schytte, Denmark 

Dynamic Changes in Cell-Free Circulating Tumor DNA to Track Tumor 

Response and Risk of Recurrence in Stage III Non-Small Cell Lung Cancer 

- Steven Lin, USA 

Discussant - Joan Schiller, USA 

Pattern of Loco-Regional Failure after Definitive Chemo Radiotherapy 

for NSCLC. Results from NARLAL, a Phase II Randomized Trial - Tine 

Schytte, Denmark 

Risk Factor of Morbidity and Mortality of Surgical Resection after 

Induction Therapy in Patients with Stage IIIA-N2 Lung Cancer - Jong Ho 

Cho, South Korea 

Mutation Profile Prognostic Value in Stage III Non Small Cell Lung Cancer 

(NSCLC) Patients Treated with Chemo-Radiotherapy (CRT) - Cecile Le 

Pechoux, France 

30


 

 

 

 

 

 

 

Incorporating Erlotinib Into Chemoradiation Therapy for Unresectable 

Stage IIIA/B NSCLC: Interim Results of Ongoing Phase II Randomized 

Trial - Jin Soo Lee, South Korea 

Discussant - Billy Loo, USA 

Isotoxic Dose Escalation and Acceleration in Lung Cancer 

Chemoradiotherapy - David Landau, United Kingdom 

Stage III NSCLC in the Elderly: Patient Characteristics Predictive for 

Tolerance and Survival of Chemoradiation in Daily Clinical Practice - 

Maryska Janssen-Heijnen, Netherlands 

Clinical Impact of Frequent Surveillance Imaging in the First Year 

following Chemoradiation for Locally Advanced Non-Small Cell Lung 

Cancer - Nima Harandi, USA 

Endostatin Combined with Paclitaxel, Carboplatin, and Radiotherapy in 

Patients with Unresectable Locally Advanced Non-Small Cell Lung 

Cancer - Yaping Xu, China 

Discussant - Corey Langer, USA 

16:45 - 18:15 Mini Oral 08: Prognostic/Predictive Biomarkers 


Moderators: Thomas Stinchcombe, USA & Nick Pavlakis, Australia 


Quantitative Mass Spectrometry Proteomics Identifies FRalpha and 

GARFT as Predictive Biomarkers in NSCLC Patients Treated With 

Pemetrexed - Abdulrahman Alshehri ?, USA 

Prediction of Response to Pemetrexed in NSCLC by 

Immunohistochemical Phenotyping Based on Gene Expression Profiles - 

Sabine Visser, Netherlands 

Tumour Molecular Profiling and Quantitative Detection of Circulating 

Biomarkers in Patients with Non-Small Cell Lung Cancer (NSCLC) - James 

Spicer, UK 

Discussant - David Spigel, USA 

VeriStrat® and Epidermal Growth Factor Receptor Mutation Status in a 

Phase 1b/2 Study of Cabozantinib +/- Erlotinib in Non-Small Cell Lung 

Cancer - Sukhmani Padda, USA 

A Survival Comparison Study of Chinese Patients with Primary Lung 

Adenocarcinoma Harboring ALK Rearrangements Detected in Different 

Methods with Crizotinib Treatment - Xiaomin Niu, China 

Prognostic Significance of FGFR1 Amplification in Patients with Lung 

Squamous Cell Carcinoma - Qi Zhang, China 

Discussant - Peter Hammerman, USA 

VEGF-Mediated Cell Survival in NSCLC: Implications for Epigenetic 

Targeting of VEGF Receptors as a Therapeutic Approach - Martin Barr, 

Ireland 

Anti-Tumor Efficacy of Interleukin-27 in Non Small Cell Lung Cancer - 

Giuseppe Cipollone, Italy 

31


Co-Occurrence of Driver Mutations of MAPK and PI3K Pathways in Non 

Small Cell Lung Cancer: A Report from Lung Cancer Genomics Ireland 

(LCGI) Study - Shereen Rafee, Ireland 

Genome-Wide Association Analysis Identifies Novel Genetic 

Determinants of Cancer Metastasis in Korean Lung Adenocarcinoma - 

Yoohwa Hwang, South Korea 

Proteomic Profiling of Pulmonary Cancer with Squamous Cell Histology - 

Hanibal Bohnenberger, Germany 

Driver Mutation Status in Resected Stage I Lung Adenocarcinoma: 

Correlation with Radiographic CT Findings - Michael Lanuti, USA 

Discussant - Justin Gainor, USA 

16:45 - 18:15 Mini Oral 09: Drug Resistance 


Moderators: Liza Villaruz, USA & John Minna, USA 

Rooms: 205 + 207 

 

 

 

 

 

 

 

 

 

 

 

 

Inhibiting Tankyrase Prevents Epithelial-To-Mesenchymal Transition and 

Synergizes with EGFR-Inhibition in Wnt-Dependent NSCLC Lines - 

Hannah Scarborough, USA 

Transcriptome-Metabolome Reprogramming of EGFR-Mutant NSCLC 

Contributes to Early Adaptive Drug-Escape via BCL-xL Mitochondrial 

Priming - Patrick Ma, USA 

Characterization of Afatinib or EGFR T790M Specific Inhibitor (WZ8040 

or AZD9291) Resistant Lung Cancer Cells (PC9) - Anya Maan-Yuh Lin, 

Taiwan 

Identification of Effective Drug Combinations to Prevent or Delay 

Resistance to the EGFR Mutant Selective Inhibitor Rociletinib (CO-1686) 

- Andrew Simmons, USA 

Discussant - Christine Lovly, USA 

Oncogenic Drivers including RET and ROS1 plus PTEN Loss and MET by 

IHC in Patients with Lung Adenocarcinomas: Lung Cancer Mutation 

Consortium 2.0 - Bruce Johnson, USA 

Activation of the MET Kinase Confers Acquired Resistance to FGFR- 

Targeted Therapy in FGFR-Dependent Squamous Cell Carcinoma of the 

Lung - Byoung Chul Cho, South Korea 

Secondary C805S Mutation in HER2 Gene Confers Acquired Resistance 

to HER2 Kinase Inhibitors in HER2 Mutant Lung Cancer - Takayuki 

Kosaka, USA 

Discussant - Edward Garon, USA 

Tumor Angiogenesis in LKB1-Mutant Non-Small Cell Lung Cancer 

(NSCLC) - Irene Guijarro, USA 

Adaptor Re-Programming and Acquired Resistance in RET-Fusion 

Positive NSCLC - Sarah Nelson, USA 

HDAC Inhibitors Overcome New Generation EGFR-TKI-Resistance 

Caused by Homozygous BIM Polymorphism in EGFR Mutant Lung Cancer 

- Seiji Yano, Japan 

32


 

 

Neuropilin-2 Promotes Acquired Resistance to EGFR-TKI Associated with 

the Epithelial?Mesenchymal Transition in Lung Cancer - Harry Drabkin, 

USA 

Discussant - Clarissa Mathias, Brazil 

16:45 - 18:15 Mini Oral 10: ALK and EGFR 


Moderators: Timothy Yap, United Kingdom & Tianhong Li, USA 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Frequency of Concomitant EGFR, EML4-ALK or KRAS Alterations in 

NSCLC Patients and Correlation with Response to Treatment - Paola 

Ulivi, Italy 

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Co- 

Altered Lung Adenocarcinoma - Weijing Cai, China 

Evolution of Concurrent Driver Mutations in Lung Adenocarcinoma 

Patients on EGFR TKI Therapy Uncovered by Comprehensive Molecular 

Profiling - Collin Blakely, USA 

Discussant - Tony Mok, Hong Kong 

ALK Rearrangements in Non-Small Cell Lung Cancer: Comprehensive 

Integration of Genomic, Gene Expression and Protein Analysis - Johanna 

Mattsson, Sweden 

Incidence of ALK Gene Rearrangements in a Prospectively, 

Consecutively Collected Caucasian Population with Pulmonary 

Adenocarcinomas - Birgit Skov, Denmark 

Lung Adenocarcinomas Co-Expressing TTF-1, MUC5B and/or MUC5AC 

Show a High Incidence of ALK Rearrangement and a Poor Prognosis - 

Dongmei Lin, China 

Discussant - Benjamin Besse, France 

Comprehensive Genomic Profiling Identifies EGFR Exon 19 Deletions in 

NSCLC Not Identified by Standard of Care Testing - Siraj Ali, USA 

A Multicenter Prospective Biomarker Study in Afatinib-Treated Patients 

with EGFR-Mutation Positive Non-Small Cell Lung Cancer - Koichi 

Azuma, Japan 

Classification of EGFR Gene Mutation Status Using Serum Proteomic 

Profiling Predicts Tumor Response in Patients with Stage IIIB or IV NSCLC 

- XiaoQing Liu, China 

Preclinical Activity of AZD9291 in EGFR-Mutant NSCLC Brain Metastases 

- Peter Ballard, United Kingdom 

Prediction of Human Pharmacokinetics, Efficacious Dose and Bbb 

Penetration of a Novel Egfr Inhibitor for Treating Nsclc with Cns 

Metastasis - Ziqiang (Zack) Cheng, China 

Brain Metastasis at Diagnosis and EGFR Mutational Status in Non-Small 

Cell Lung Cancer - Apar Ganti, USA 

Discussant - Oscar Arrieta Rodriguez, Mexico 

33


16:45 - 18:15 Mini Oral 11: Tobacco Control and Prevention 


Moderators: Sam Janes, United Kingdom & Emily Stone, Australia 

Rooms: 601 + 603 

The Upshot of Passive Smoke (ETS) Exposure on Pneumonia Risk in 

Children Under 7 Years in Nigeria - Blessing Obiazi-Odiase, Nigeria 

Frizzled9 as a Predictor of Response to Iloprost Chemoprevention of 

Lung Cancer - Meredith Tennis, USA 

Switching to Smokeless Tobacco Use as a Smoking Cessation Method in 

India - Gomathyamma Mini, India 

A New Preclinical Model of Airway Progenitor Cells to Identify 

Responders to Iloprost-Mediated Chemoprevention - Moumita Ghosh, 

USA 

Prevalence Use of Others Tobacco Products: Findings from the ITC Brazil 

Survey - Cristina Perez, Brazil 

Comprehensive Tobacco Control Programs Reduce Tobacco Use and 

Secondhand Smoke Exposure: A Systematic Review - Jeffrey Reynolds, 

USA 

The Relationship between Smoking Status and Prognostic Factors after 

Surgery in Lung Cancer Patients with Chronic Obstructive Pulmonary 

Disease - Masaya Yotsukura, Japan 

Smoking Cessation Results in a Clinical Lung Cancer Screening Program - 

Andrea Borondy Kitts, USA 

Trends in Lung Cancer Mortality Attributable to Smoking, Years of 

Potential Life Lost and Financial Cost, Puerto Rico 1983-2010 - Cecile 

Marques-Goyco, Puerto Rico 

Quality of Lung Cancer Treatment in Two Neighbouring Regions of 

Germany and Denmark - Niels Henrik Holländer, Denmark 

Lung Cancer and Smoking in Nepal - Madan Piya, Nepal 

Is There Any Role for Residential Radon in Patients with Non Small Cell 

Lung Cancer (NSCLC) Harbouring Molecular Alterations? Preliminary 

Results - Pilar Garrido, Spain 

16:45 - 18:15 Mini Oral 12: Biomarkers and Lung Nodule Management 


Moderators: Jill Siegfried, USA & Harvey Pass, USA 

Rooms: 401 - 404 

A Novel Serum 4-MicroRNA Signature for Lung Cancer Detection - 

Ernest Nadal, Spain 

Clinical Utility of Chromosomal Aneusomy in High Risk Individuals - 

Anna Barón, USA 

Comprehensive Analysis of MicroRNA Expression Patterns in Lung 

Adenocacinoma Presenting with GGNs and Non-Tumorous Tissues - Yayi 

He, China 

34


Blinded Evaluation of the LuCED test to Detect Early Stage Lung Cancer - 

Michael Meyer, USA 

Discussant - Luis Montuenga, Spain 

Bioconductance Compared to 18FDG-PET in Evaluating CT-Detected 

Lung Lesions - Rex Yung, USA 

Exhaled Breath Analysis in Lung Cancer - One Stop Shop for Diagnosis, 

Staging and EGFR Analysis - Nir Peled, Israel 

Validation of Autoantibody Panel for Early Detection of Lung Cancer in 

Chinese Population - Shengxiang Ren, China 

Progress with an RCT of the Detection of Autoantibodies to Tumour 

Antigens in Lung Cancer Using the Early CDT-Lung Test in Scotland 

(ECLS) - Frank Sullivan, Canada 

Discussant - Harvey Pass, USA 

Screening for Lung Cancer with the Early CDT-Lung and Computed 

Tomography - James Jett, USA 

Validation of Blood-Based Biomarker for Classification of Patients with 

Indeterminate Pulmonary Nodules - Charlie Birse, USA 

Early Detection of Lung Cancer Using DNA Methylation in Plasma and 

Sputum - Alicia Hulbert, USA 

Exhaled microRNAs as Potential Biomarkers of Lung Cancer Case versus 

Control Status - Simon Spivack, USA 

Discussant - Avrum Spira, USA 

18:30 - 20:00 Symposium supported by Clovis Oncology: Critical Insights on Mutant-Specific 

Epidermal Growth Factor Receptor Inhibitors for NSCLC 

Chair: Edward Kim, USA 

Room: 601 + 603 

Website: www.ecgcme.com/T790M 

First- and Second-Generation EGFR TKIs in Mutant-Unselected and 

Mutant-Sensitive NSCLC - Lecia Sequist 

Third-Generation EGFR TKIs in Mutant-Specific NSCLC - Jonathan 

Goldman 

Exploring the Use of Immunotherapy EGFR-TKI Resistance in NSCLC - 

David Gandara 

Thoughts From the Chair - Edward Kim 

20:00 – 23:00 Faculty Dinner (by invitation only) 

Room: Seawell Ballroom, Denver Center for the Performing Arts 

35

Tuesday, September 8, 2015 


07:00 - 08:00 Symposium supported by Myriad: Improving the Care of Patients with Early- 

Stage Lung Adenocarcinoma: Role of Prognostic Signatures 

Rooms: 201 + 203 

Symposium supported by Celgene: The New Frontier in NSCLC - Beyond EGFR, 

VEGF and ALK: Expanding the Paradigm to Include Patients Without 

Actionable mutations - CRITICAL QUESTIONS and CASE BASED LEARNING 

Speakers: Mark Socinski, USA & Roy Herbst, USA & Gregory Riely, USA 

Room: Mile High Ballroom 2 + 3 

 

Webpage: www.bmli.com/live/nsclc/index.php 

The target audience for this symposium on managing NSCLC patients without 

actionable mutations includes medical oncologists, hematologists, radiation 

oncologists, surgical oncologists, pathologists, Fellows, Physician Assistants, 

oncology nurses/Nurse Practitioners, oncology pharmacists, and other allied 

health-care professionals involved in the treatment, care and management of 

patients with NSCLC. Lung cancer is treated optimally by a multi-disciplinary 

approach and, thus, all of the aforementioned clinician specialties are invited to 

participate in this symposium. 

Symposium supported by Pfizer: Recent Advancements in the Identification 

and Treatment of ALK+ Metastatic NSCLC 

Room: 401 - 404 

07:00 - 08:00 Highlights of the Previous Day HOD 01: Treatment of Advanced, Localized and 

LocoRegional Disease and Small Cell, Thymoma, Mesothelioma 

Track: Highlights from Monday, September 7 


 

 

 

 

Treatment of Advanced Disease - Yi-Long Wu, China 

Treatment of Localized Disease - Jessica Donington, USA 

Treatment of LocoRegional Disease - Chandra Belani, USA 

Small Cell/Thymoma/Mesothelioma/Other – Martin Edelman, USA 

07:00 - 08:00 Highlights of the Previous Day HOD 02: Biology, Pathology, Molecular Testing, 

Prevention, Tobacco Control, Screening and Early Detection 

Track: Highlights from Monday, September 7 


 

Biology, Pathology, Molecular Testing - Kenneth O'Byrne, Australia 

36


 

 

Prevention, Tobacco Control - Carolyn Dresler, USA 

Screening, Early Detection - Claudia Henschke, USA 

07:00 - 08:00 MTE 12: Meet the Expert: Therapy for Driver Mutation Positive Advanced 

NSCLC (Ticketed Session) 


Speaker: Federico Cappuzzo, Italy 

Room: 103 

07:00 - 08:00 MTE 13: Meet the Expert: Standard of Care in Rare Thoracic Malignancies 



Speaker: Nicolas Girard, France 

Room: 105 

07:00 - 08:00 MTE 14: Meet the Expert: Proposal of Revised (8th) Edition of TNM Staging 

System for Lung Cancer (Ticketed Session) 

Track: Treatment of Localised Disease - NSCLC 

Speaker: Mark Krasnik, Denmark 

Room: 107 

07:00 - 08:00 MTE 15: Meet the Expert: Management of Major Airway and Vascular 

Obstruction (Ticketed Session) 


Speaker: Georgios Stamatis, Germany 

Room: 109 

07:00 - 08:00 MTE 16: Meet the Expert: Living with Cancer and Sexuality (Ticketed Session) 


Speaker: Luca Incrocci, Netherlands 

Room: 111 

07:00 - 08:00 MTE 17: Meet the Expert: Dealing with Metastatic Bone Disease in Lung 

Cancer - Prevention of SREs and Pain (Ticketed Session) 


Speaker: Vera Hirsh, Canada 

Room: 102 + 104 + 106 

37


07:00 - 08:00 MTE 18: Meet the Expert: Chemoprevention Trials: Past, Present, and Future 



Speaker: Dennis Wigle, USA 

Room: 108 + 110 + 112 

07:00 - 08:00 MTE 19: Meet the Expert: Electronic Nicotine Delivery Devices (ENDS): 

eCigarettes (Ticketed Session) 


Speaker: Kenneth Cummings, USA 

Room: 702 + 704 + 706 

07:00 - 08:00 MTE 20: Meet the Expert: Biology and Pathology of Neuroendocrine Cancers: 

Small Cell Lung Cancer - Call for Action (Ticketed Session) 


Speakers: Keith Kerr, United Kingdom & Ilona Linnoila, USA 

Room: 708 + 710 + 712 

07:00 - 08:00 MTE 21: Meet the Expert: Early Detection of Central Airway Lesions: Biology 

and Practical Clinical Approaches (Ticketed Session) 


Speakers: Annette McWilliams, Australia & Gabriella Sozzi, Italy 

Room: 703 

 

 

Early Detection of Central Airway Lesions: Biology and Practical Clinical 

Approaches - Annette McWilliams, Australia 

Biomarkers for Early Detection of Lung Cancer - Gabriella Sozzi, Italy 

07:00 - 08:00 MTE 22: Meet the Expert: Diagnosis and Treatment of MPM: Overview 



Speaker: Arnauld Scherpereel, France 

Room: 205 + 207 

08:15 - 09:45 Plen 02: Plenary Session: Lung Cancer: IASLC Global Initiatives 


Chairs: Fred R. Hirsch, USA & Silvia Novello, Italy 


 

2015 WHO Classification of the Pathology and Genetics of Tumors of the 

Lung - William Travis, USA 

38


 

Revised (8th) Edition of TNM Staging System for Lung Cancer - Ramon 

Rami-Porta, Spain 





Moderator: Dr. Everett Vokes, Congress Co-Chair, John Ultmann Professor and 

Chair, Department of Medicine at the University of Chicago 

Room: 108 + 110 + 112 

 

 

 

 

 

 

 

 

Daily Theme: Lung Cancer: A Women’s Disease - Dr. Silvia Novello, 

Associate Professor, Department of Oncology, University of Turin-Italy 

Revised (8th) Edition of TNM Staging System for Lung Cancer - Dr. 

Ramon Rami-Porta, Thoracic Surgery Service, Hospital Universitari 

Mutua Terrassa, Barcelona, Spain 

2015 WHO Classification of the Pathology and Genetics of Tumors of the 

Lung - Dr. William Travis, Attending Thoracic Pathologist, Dept. of 

Pathology, Memorial Sloan Kettering Cancer Center, New York 

Abstract – Increasing Incidence of Non-Smoking Lung Cancer: 

Presentation of Patients with Early Disease to a Tertiary Institution in 

the UK - Dr. Eric Lim, Royal Brompton and Harefield NHS Trust, London 

Abstract – Increasing Incidence of Never Smokers in Non Small Cell Lung 

Cancer (NSCLC) Patients - Dr. Lorraine Pelosof, Assistant Professor, UT 

Southwestern Medical Center, Dallas, Texas 

Abstract – Oncogenic Profiling in Lung Adenocarcinoma Emerged in the 

Youth - Dr. Kosuke Tanaka, Department of Cancer Genetics, Nagoya 

University Graduate School of Medicine; Division of Molecular 

Oncology, Aichi Cancer Center Research Institute, Japan 

Abstract – The Genomics of Young Lung Cancer Study - Dr. Barbara 

Gitlitz, Associate Professor of Clinical Medicine at USC Keck School of 

Medicine, Los Angeles 

Q & A 

09:50 - 10:40 Exhibit Showcase Session: Lilly: Shared Voice – Individualizing Patient – 

Centered Communication for Advanced Lung Cancer Patients 


10:45 - 12:15 Oral Session 16: Clinical Care of Lung Cancer and Advanced Biopsies 


Moderators: Joel Neal, USA & Qinghua Zhou, China 

39



 

 

 

 

 

 

 

 

Tyrosine Kinase Inhibitors (TKIs) for the Treatment of Brain Metastases 

(BMs) from Advanced Lung Cancer : A Large Retrospective Cohort Study 

- Chiara Bennati, Italy 

Thromboembolic and Bleeding Risk with Adjuntctive LMWHs 

Anticoagulation in Lung Cancer Patients. Meta-Analysis of Randomized 

Trials - Janusz Kowalewski, Poland 

Acceptability of NSCLC, NOS in Advanced Disease: An Assessment of US 

Oncologists, Pulmonologists and Pathologists - Tara Herrmann, USA 

Discussant - Robert Pirker, Austria 

Retrospective Analysis of ctDNA EGFR Mutations in the Phase III, 

Randomized IMPRESS Study - Kenneth Thress, USA 

Quantification of Mutant Alleles in Circulating Tumor DNA from 

Advanced Non-Small Cell Lung Cancer - Jie Wang, China 

Intratumor Heterogeneity of EGFR Activating Mutations Analyzed in 

Single Cancer Cells in Advanced NSCLC Patients - Qiuyi Zhang, China 

Discussant - Philip Mack, USA 

10:45 - 12:15 Oral Session 17: EGFR Mutant Lung Cancer 


Moderators: Peter Meldgaard, Denmark & Enriqueta Felip, Spain 


 

 

 

 

 

 

 

 

 

First-Line Icotinib versus Cisplatine/Pemetrexed plus Pemetrexed 

Maintenance in Advanced NSCLC Patients with EGFR Mutation - Yuankai 

Shi, China 

Randomized Trial of Gefitinib with and without Pemetrexed as First-Line 

Therapy in East-Asian Patients with Advanced NS NSCLC with EGFR 

Mutations - Ying Cheng, China 

Biomarkers for Efficacy in JO25567 Study Evaluating Erlotinib plus 

Bevacizumab versus Erlotinib in Advanced NSCLC with EGFR Mutation - 

Shinji Atagi, Japan 

Discussant - Lecia Sequist, USA 

Clinical Outcomes in Patients with Non-Small-Cell Lung Cancer (NSCLC) 

Harboring Rare Epidermal Growth Factor Receptor (EGFR) Mutations - 

Pedro Domingues, Brazil 

Phase I/II Study of INC280 plus Erlotinib in Patients with MET Expressing 

Adenocarcinoma of the Lung - Caroline McCoach, USA 

Mechanisms of Acquired Resistance to AZD9291 in EGFR T790M Positive 

Lung Cancer - Geoffrey Oxnard, USA 

Gefitinib/Chemotherapy vs Chemotherapy in EGFR Mutation-Positive 

NSCLC Resistant to First-Line Gefitinib: IMPRESS T790M Subgroup 

Analysis - Tony Mok, Hong Kong 

Discussant - Tetsuya Mitsudomi, Japan 

40


10:45 - 12:15 Oral Session 18: Non PD1 Immunotherapy and Angiogenesis 


Moderators: Charles Butts, Canada & Karen Reckamp, USA 

Room: Four Seasons Ballrom F1 + F2 

 

 

 

 

 

 

 

TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of 

Advanced NSCLC: Phase 2b Results - Elisabeth Quoix, France 

MUC1-Targeted Dendritic Cell-Based Vaccine Immunotherapy in 

Patients with Standard Treatments-Refractory Non-Small-Cell Lung 

Cancer - Koji Teramoto, Japan 

Discussant - Johan Vansteenkiste, Belgium 

Anti-Angiogenic Therapy in Advanced Non-Small Cell Lung Cancer 

(NSCLC): A Meta-Analysis of Phase 3 Randomized Trials - Jacques 

Raphael, Canada 

Early Predictive Value of Perfusion-Computed Tomography (pCT) in 

Advanced NSCLC Patients Treated with Bevacizumab: IMPACT Trial - 

Fran Aya, Spain 

Effect of Anti-VEGF Therapy on MDSCs' Population in the Peripheral 

Blood of Non-Small Cell Lung Cancer (NSCLC) Patients - Athanasios 

Kotsakis, Greece 

Discussant - Primo Lara Jr., USA 

10:45 - 12:15 Oral Session 19: Radiation for Localized Lung Cancer 


Moderator: Dirk De Ruysscher, Belgium 

Rooms: 102 + 104 + 106 

The SPACE Study: A Randomized Phase II Trial Comparing SBRT and 

3DCRT in Stage I NSCLC Patients; Final Analysis including HRQL - 

Andreas Hallqvist, Sweden 

Higher Risk of Failure and Death after Stereotactic Lung Radiotherapy 

for T2 Lung Cancer - Matthew Johnson, USA 

NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiotherapy 

(SBRT) for Central Tumors - Adverse Events - Andrea Bezjak, Canada 

Discussant - Francoise Mornex, France 

Japanese Multicenter Study of Stereotactic Body Radiotherapy for 661 

Medically Operable Patients with Stage I Non-Small Cell Lung Cancer - 

Takafumi Komiyama, Japan 

Tumor Location Is Associated with Recurrence Pattern and Survival after 

SBRT in Early Stage NSCLC Patients - Barbara Stam, Netherlands 

A Novel Nomogram for Predicting Distant Metastases after Lung 

Stereotactic Body Radiotherapy for Early Stage Lung Cancer - Steven Oh, 

USA 

41


10:45 - 12:15 Oral Session 20: Chemoradiotherapy 


Moderators: George Blumenschein, USA & Joe Chang, USA 

Rooms: 201 + 203 

 

 

 

 

 

 

 

 

A Systematic Review of Carboplatin-Paclitaxel versus Cisplatin-Etoposide 

Concurrent with Thoracic Radiation for Stage III NSCLC Patients - Conor 

Steuer, USA 

Safety Results of the Consolidation Phase of a Phase III (PROCLAIM): 

Pemetrexed, Cisplatin or Etoposide, Cisplatin plus Thoracic Radiation 

Therapy followed by Consolidation Cytotoxic Chemotherapy in Locally 

Advanced Nonsquamous Non-small Cell Lung Cancer - Ramaswamy 

Govindan, USA 

Radiation Dose Escalation in Patients with Locally Advanced Non-Small 

Cell Lung Cancer; 60 Month Follow-Up of a Randomized Phase II Trial - 

Jose Belderbos, Netherlands 

Discussant - Gregory Videtic, USA 

Elective Nodal Irradiation Does Not Alter Isolated Nodal Failure and 

Survival Outcomes in Stage III NSCLC Patients Undergoing 

Chemoradiotherapy - Erkan Topkan, Turkey 

Outcomes of Intensity Modulated and 3D-Conformal Radiotherapy for 

Stage III Non-Small Cell Lung Cancer in NRG Oncology/RTOG 0617 - 

Stephen Chun, USA 

Survival Impact of Post-Operative Therapy Modalities after Incomplete 

and Complete Surgical Resection for Non-Small Cell Lung Cancer in the 

US - Matthew Smeltzer, USA 

Discussant - Andrea Bezjak, Canada 

10:45 - 12:15 Oral Session 21: Biology - Moving Beyond the Oncogene to Oncogene- 

Modifying Genes 


Moderator: Artur Katz, Brazil 


Adaptive Survival Signaling in Oncogenic Fusion Kinase Addicted NSCLC - 

Aria Vaishnavi, USA 

Landscape and Functional Significance of KRAS Co-Mutations in Lung 

Adenocarcinoma (LUAC) - Ferdinandos Skoulidis, USA 

KEAP1-Mutations and NFE2L2-Mutations in Patients with Non-Small Cell 

Lung Cancer (NSCLC) - Rieke Frank, Germany 

Discussant - Daniel Morgensztern, USA 

p53/KRAS mutation status does not predict sensitivity to chemotherapy 

in NSCLC PDXs - Céline Mascaux, Canada 

Two Faces of YAP: Oncogenic in Lung Tumor Malignant Progression but 

Inhibitory in Phenotypic Transition - wenjing Zhang, China 

Discussant - Francesco Grossi, Italy 

42


10:45 - 12:15 Oral Session 22: Moving Beyond a Smoking Related-Cancer to the Young, 

Never-smokers and Inherited Disease 


Moderators: Kenichi Suda, Japan & Heather Wakelee, USA 


Increasing Incidence of Never Smokers in Non Small Cell Lung Cancer 

(NSCLC) Patients - Lorraine Pelosof, USA 

Spectrum of Cancer Types in Kindreds with NSCLC and EGFR T790M 

Mutations: Results from INHERIT EGFR - Georgia Wiesner, USA 

Inter-, and Intratumoural Genomic Heterogeneity of Primary Pulmonary 

Adenocarcinoma in Never Smokers - Marissa Daniels, Australia 

Discussant - Paolo Boffetta, USA 

The Genomics of Young Lung Cancer Study - Barbara Gitlitz, USA 

Whole Exome Sequencing to Profile the Genomic Landscapes of Young 

Patients (pts) Diagnosed with Non-Small Cell Lung Cancer (NSCLC) - 

Patrick Ma, USA 

Oncogenic Profiling in Lung Adenocarcinoma Emerged in the Youth - 

Kosuke Tanaka, Japan 

Discussant - Benjamin Levy, USA 

10:45 - 12:15 Oral Session 23: Prevention and Cancer Risk 


Moderators: Nico van Zandwijk, Australia & Nasser Hanna, USA 

Rooms: 601 + 603 

 

 

 

 

 

 

 

 

A Randomized Phase IIb Trial of Myo-Inositol in Smokers with Bronchial 

Dysplasia - Stephen Lam, Canada 

Pioglitazone for the Chemoprevention of Lung Cancer - Robert Keith, 

USA 

Role of Inflammatory Infiltrates in Promoting Persistence or Regression 

of Bronchial Dysplasia - Daniel Merrick, USA 

Discussant - Eva Szabo, USA 

Increased Proportion of Female and Young Mesothelioma Cases Are 

Indicators of Environmental Exposure to Carcinogenic Mineral Fibers in 

Nevada - Francine Baumann, USA 

Radon Gas Exposure and Lung Cancer in a Cohort of Lung Cancer 

Patients Who Never Smoked - Gwyn Bebb, Canada 

Interactions Between Smoking and the Dietary Inflammatory Index in 

Relation to Lung Cancer in the Prostate Lung Colorectal and Ovarian 

Trial - Azza Shoaibi, USA 

Discussant - Michele Carbone, USA 

10:45 - 12:15 Oral Session 24: CT Detected Nodules - Predicting Biological Outcome 


Moderators: Kavita Garg, USA & Keith Kerr, United Kingdom 

43


Rooms: 401 - 404 

 

 

 

 

 

 

 

 

Natural History of Pulmonary Subsolid Nodules: A Prospective 

Multicenter Study - Ryutaro Kakinuma, Japan 

Quantification of Growth Patterns of Screen-Detected Lung Cancers: 

The NELSON Trial - Marjolein Heuvelmans, Netherlands 

Increasing Incidence of Non-Smoking Lung Cancer: Presentation of 

Patients with Early Disease to a Tertiary Institution in the UK - Maria 

Elena Cufari, United Kingdom 

Discussant - Giulia Veronesi, Italy 

Reclassification of Lung Cancers Detected by CT Imaging in the American 

College of Radiology Imaging Network National Lung Screening Trial* - 

Wilbur Franklin, USA 

Stratification of Lung Adenocarcinomas in the National Lung Screening 

Trial - Tobias Peikert, USA 

Behavior Differences of Screen-Detected Lung Cancers in the CT Arm of 

the National Lung Screening Trial (NLST) - Matthew Schabath, USA 

Discussant - Masayuki Noguchi, Japan 

10:45 - 12:15 Oral Session 25: Biology and Other Issues in SCLC 


Moderators: Julien Sage, USA & Luis Montuenga, Spain 

Rooms: 605 + 607 

 

 

 

 

 

 

 

 

Screening for Small Cell Lung Cancer: Analysis of the National Lung 

Cancer Screening Trial Data - Anish Thomas, USA 

Vasculogenic Mimicry in Small Cell Lung Cancer - Caroline Dive, United 

Kingdom 

Establishment of Lung Cancer Xenograft Models Derived from 

Bronchoscopy Biopsy and Investigating Mechanism of Refractory Small 

Cell Lung Cancer - Jie Wang, China 

Discussant - Charles Rudin, USA 

Predictive and Prognostic Significance of Myeloid-Derived Suppressor 

Cells in Patients with Small-Cell Lung Cancer - Ying Cheng, China 

Association of Expression of PD-L1 with the Tumor Immune 

Microenvironment in Small Cell Lung Cancer - Hui Yu, USA 

DNA Methylation in Small Cell Lung Cancer Defines Distinct Disease 

Subtypes and Correlates with High Expression of EZH2 - John Poirier, 

USA 

Discussant - Caroline Dive, United Kingdom 

10:45 - 12:15 Oral Session 26: Clinical Trials 2 


Moderators: Arnaud Scherpereel, France & Charles Thomas, USA 

Rooms: 702 + 704 + 706 

44


 

 

 

 

 

 

 

 

Initial Analyses of the IASLC Malignant Pleural Mesothelioma (MPM) 

Database: Implications for the 8th Edition AJCC and UICC Staging 

Manuals - Valerie Rusch, USA 

What Are the Risks and Benefits of Extended Pleurectomy Decortication 

for Mesothelioma? A Review of the Largest Institutional Series in the UK 

- Annabel Sharkey, United Kingdom 

Predictive and Prognostic Value of Clinical TNM Staging for Patients with 

Malignant Pleural Mesothelioma Undergoing Surgery - Ritu Gill, USA 

Discussant - Marc de Perrot, Canada 

Symptom Study of Radiotherapy in Mesothelioma (SYSTEMS), a Phase II 

Study - Noelle O'Rourke, United Kingdom 

Prospective Assessment of Proton Therapy for Malignant Pleural 

Mesothelioma - Yun Li, USA 

Early Signs of Clinical Activity of a MicroRNA-Based Therapy in a Phase I 

Study in Recurrent Malignant Pleural Mesothelioma - Nico van 

Zandwijk, Australia 

Discussant - Andreas Rimner, USA 

10:45 - 12:15 Oral Session 27: Care 


Moderators: Merel Nissenberg Mountain, USA & Janet Freeman-Daily, USA 

Rooms: 708 + 710 + 712 

 

 

 

 

 

 

 

 

Bridging the Quality Chasm in Lung Cancer Care: Stakeholder 

Perspectives on Multidisciplinary Care in a Community Hospital Setting - 

Raymond Osarogiagbon, USA 

Patients' Attitudes and Physicians' Perceptions Toward Maintenance 

Therapy for Advanced NSCLC: A Multicenter Italian Survey - Maria 

Vittoria Pacchiana, Italy 

Patient Advocates in the Lung Cancer Diagnostic Pathway: A Qualitative 

Study of Interviews with Lung Cancer Patients and Their Caregivers - 

Nicole Rankin, Australia 

Discussant - Guneet Walia, USA 

"Care for Outcome" in Lung Cancer: A Santeon's Value Based Health 

Care Project - C.M. van Loenhout, Netherlands 

Disparities in Lung Cancer Incidence and Management Care in France: A 

Nationwide Cohort Study (the TERRITOIRE Study) - Christos Chouaid, 

France 

Impact of Regulatory Delays in Approving Oncology Drugs in a 

Developing Country: Mortality Associated with Lack of Access to 

Crizotinib in Brazil - Pablo Barrios, Brazil 

Discussant - Jim Baranski, USA 

10:45 - 12:15 Mini Oral 13: Genetic Alterations and Testing 


Moderators: Yasuhiro Koh, Japan & Roman Thomas, Germany 

45


Rooms: 205 + 207 

Clinicopathological Profiles of ROS1 Positive Patients Screened by FISH - 

Jamie Sheren, USA 

Detection of ALK Rearrangement and EGFR Mutation in Primary 

Pulmonary Lymphoepithelioma-Like Carcinoma - Ying Liang, China 

Characterization of MET Gene and MET Protein Expression in Lung 

Cancer - Theresa Boyle, USA 

Characterization of Gene Mutations and Copy Number Alterations in 

Chinese Squamous Cell Lung Carcinomas - Yuankai Shi, China 

Discussant - Marc Ladanyi, USA 

Mutation Prevalence for Oncogenic Drivers in Lung Adenocarcinoma - 

Christopher Rivard, USA 

Kinome Targeted Deep Sequencing Identifies Novel Mutations in Korean 

Adenocarcinoma of the Lung - Yoohwa Hwang, South Korea 

Targetable Genomic Aberrations in Squamous Cell Lung Cancer (SCC): A 

Report from the Lung Cancer Genomics Ireland (LCGI) Study - Shereen 

Rafee, Ireland 

Next-Generation Sequencing Analysis of Driver Gene Mutations in 

Pleomorphic Carcinoma of the Lung - Saki Manabe, Japan 

Discussant - Lucian Chirieac, USA 

Detection of Rare Clinically Actionable Mutations in NSCLC Metastatic to 

the Brain by Targeted Next Generation Sequencing - Laura Tafe, USA 

The Abundance of EGFR Mutations Could Be More Better Predictor for 

EGFR-TKI Therapy in Advanced Non-Small Cell Lung Cancer - Xuefei Li, 

China 

Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR Mutations (EGFRm) 

and Breast Cancer (BC): A Retrospective Analysis - enric Carcereny, 

Spain 

S768I Mutation in the EGFR Gene in Patients with Lung Cancer - 

Konstantinos Leventakos, USA 

Discussant - Lynette Sholl, USA 

10:45 - 12:15 Mini Oral 14: Pre-Clinical Therapy 


Moderator: Lynnette Fernandez-Cuesta, France & Adi Gazdar, USA 


 

 

 

 

EGFR-Mutated PDX in NSCLC: Molecular Fidelity and Correlation of PDX 

and Patient Response to EGFR Inhibition - Jonathan Riess, USA 

TAE226, a Bis-Anilino Pyrimidine Compound, Shows Anti-Tumor Effect 

on EGFR-Mutant Non-Small Cell Lung Cancer Cells including T790M 

Mutant - Hiromasa Yamamoto, Japan 

New Monoclonal Antibody Targeting on Basic Fibroblast Growth Factor 

against Lung Cancer In Vitro and In Vivo - Meng Xu, China 

In Vitro and in Vivo Evaluation of the Kinase Inhibitor, MGCD516, in TRK 

and RET Fusion Cancer Cells - Robert Doebele, USA 

46


Discussant - James DeGregori, USA 

High-Affinity α3β1 Integrin Ligand LXY30 for the Screening, Imaging and 

Targeted Drug Delivery in Non-Small Cell Lung Cancer (NSCLC) - 

Tianhong Li, USA 

Bavituximab Activates CD8+ TILs in a 3D Ex Vivo System of Lung Cancer 

Patients Derived Tumors With Negative PD-L1 Expression - Soner Altiok, 

USA 

HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung 

Adenocarcinoma Cells and Inhibits Lung Cancer Stem Cells - Vera 

Levina, USA 

Discussant - Rafal Dziadziuszko, Poland 

CAY10603, a Novel Inhibitor of HDAC6, Suppresses Non-Small Cell Lung 

Cancer Cell Growth via Modulating Both Autophagy and Apoptosis 

Pathways - Zhihao Wang, China 

Establishment of a Lung Cancer Patient-Derived Xenografts Panel - 

Mattia Boeri, Italy 

Genomic Profiling of Patient-Derived Xenografts Identify Passenger 

Aberrations Associated with Better Prognosis in Non-Small Cell Lung 

Cancer - Nhu-An Pham, Canada 

Small Molecule Demonstrates Potent Tumor Suppression by Inhibiting 

the PI3K/AKT Pathway in Non-Small Cell Lung Cancer - Gavitt Woodard, 

USA 

Suppression of Lung Cancer Growth by CD26/DPP4 Inhibitor - Ignacio 

Gil-Bazo, Spain 

Discussant - Federico Cappuzzo, Italy 

12:30 - 13:00 Exhibit Showcase Session by Guardant Health: Guardant Health: Guardant360: 

Clinical Impact of Biopsy-Free Tumor Sequencing in NSCLC 

Speaker: Richard Lanman, USA 


12:30 - 14:00 Symposium supported by Merck: Immuno-Oncology in Advanced NSCLC: Debates 

and Controversies 


 

http://medscape.org/townhall/io-nsclc 

14:15 - 15:45 GR 01: Grand Rounds: Management of challenging clinical scenarios in 

localized lung cancer 


Chairs: John Mitchell, USA & Gail Darling, Canada 

Rooms: 601 + 603 

 

T4 NSCLC Involving the Great Vessels: Role for resection? - David 

Harpole, USA 

47


 

 

 

Should All Lung Tumors Invading the Chest Wall be Treated Like 

Pancoast Tumors? - Brendon Stiles, USA 

T4 Lung Tumors According to the New Classification - What is the Role 

of Surgery? - Daniel Boffa, USA 

Salvage Surgery After Definitive Chemoradiation Therapy (CRT) - Eric 

Vallieres, USA 

14:15 - 15:45 GR 02: Grand Rounds: Difficult Mesothelioma Cases 

Track: Thymoma, Mesothelioma & other Thoracic Malignancies / Nursing and 

Allied Professionals 

Chairs: Jaime de la Garza, Mexico & Andreas Rimner, USA & Anne Tsao, USA 

Rooms: 102 + 104 + 106 

Case 1: A 70 Year Old with a Biphasic Stage I MPM - Harvey Pass, USA 

Case 2: A 65 Year Old with an Uncytoreduceable MPM - Paul Baas, 

Netherlands 

Case 3: A 65 Year Old with a Clinical Stage II MPM and Chest Pain - 

Joseph Friedberg, USA 

Addressing the Needs of the Mesothelioma Patient Who Has Exhausted 

Treatment Options: Palliation and Support for Family and Patient - 

Helen Clayson, United Kingdom & Liz Darlison, United Kingdom & 

Mary Hesdorffer, USA 

14:15 - 15:45 MS 11: Mini Symposium: New Approaches to Combined Modality Therapy for 

Stage III Disease 


Chairs: David Jablons, USA & Jan van Meerbeeck, Belgium 

Rooms: 605 + 607 

 

 

 

 

The Future of Radiation Therapy in Combined Modality Therapy - Rafal 

Dziadziuszko, Poland 

Future Role of Surgery (Timing, Patient Selection, and New Techniques) 

- Walter Weder, Switzerland 

New Systemic Approaches (Targeted Therapies and Immune Therapies) 

- Hossein Borghaei, USA 

Overview of Current International Randomized Trials - Simon Ekman, 

Sweden 

14:15 - 15:45 MS 12: Mini Symposium: NSCLC Stems Cells: Are They a Real Target? 


Chairs: Caroline Dive, United Kingdom & Kazuhiko Nakagawa, Japan 


 

Biology of Cancer Stem Cells - Neil Watkins, Australia 

48


 

 

 

Current Therapeutic Targets and Ongoing Trials - Maximilian Diehn, 

USA 

Where To Go From Here? - Rafael Rosell, Spain 

Tumor-Propagating Cells in Non-Small Cell Lung Cancers - Carla Kim, 

USA 

14:15 - 15:45 MS 13: Mini Symposium: The Other “–omics” 


Chairs: James Herman, USA & Ite Laird-Offringa, USA 


 

 

 

 

Epigenomics - James Herman, USA 

Proteomics and Phosphoproteomics - Eric Haura, USA 

Genomics – Beyond the Driver Oncogene (Role of Tumor Suppressors, 

TP53, LKB1, PTEN, etc.) - Kwok-Kin Wong, USA 

Integrating “omics” for a Unified View of Lung Cancer - James Spicer, 

United Kingdom 

14:15 - 15:45 MS 14: Mini Symposium: Chemo Prevention Clinical Trials 


Chairs: York Miller, USA & Pieter E. Postmus, Netherlands 

Rooms: Room 401 - 404 

 

 

 

 

Preclinical Models: How Good Are They? - Robert Keith, USA 

Clinical Trials: Who Are the Proper Cohorts and How Do You Recruit 

Subjects? - Stephen Lam, Canada 

Pathologic Biomarkers of Risk and Benefit of Treatment – Dan Merrick, 

USA 

Chemoprevention Clinical Trials: How Do We Move Forward? How Do 

We Identify Valid End Points? - Eva Szabo, USA 

14:15 - 15:45 MS 15: Mini Symposium: Current Screening Trials, Current Evidence and 

Screening Algorithms 


Chairs: Peter Mazzone, USA & Tatiana Vidaurre-Rojas, Peru 


 

 

 

 

NLST, USPSTF recommendations —Is Screening Going to Happen in 

USA? - James Mulshine, USA 

NELSON Emerging Data - Harry de Koning, Netherlands 

UKLS Impact of Utilization of Risk Assessment in Trial Selection - John 

Field, United Kingdom 

Screening in Japan - the JECS Study - Motoyasu Sagawa, Japan 

49


14:15 - 15:45 MS 16: Mini Symposium: Novel SCLC Therapies 


Chairs: Carlos Barrios, Brazil & Nagahiro Saijo, Japan 


PARP Inhibitors and DNA Damage - Lauren Byers, USA 

Stem Cell/Notch/Hedgehog - David Carbone, USA 

PI3K/AKT/mTOR - Shigeki Umemura, Japan 

Immunotherapy (Checkpoint Inhibitors) - Martin Reck, Germany 

Aurora Kinase and Cyclin Kinase Inhibitors - Clarissa Mathias, Brazil 

New Chemotherapies (Eribulin, Aldoxorubicin, Etirinotecan, MM398) - 

Ramaswamy Govindan, USA 

14:15 - 15:45 MS 17: Mini Symposium: Immunotherapy for Mesothelioma 


Chairs: Dean Fennell, United Kingdom & Takashi Nakano, Japan 

Rooms: 201 + 203 

 

 

 

 

Overview: Immunotherapy in Mesothelioma - Anna Nowak, Australia 

Immunotoxins and Mesothelin Antibody - Raffit Hassan, USA 

DC Vaccination - Joachim Aerts, Netherlands 

CTLA4 and PD-1 - Hedy Lee Kindler, USA 

14:15 - 15:45 MS 18: Mini Symposium: Advocacy Snapshots 


Chairs: Patricia Mondragon, Mexico & Kim Norris, USA 

Room: 703 

Tobacco Controls Impact on Lung Cancer - Glenda Colburn, Australia 

Advocates Making a Responsible Case for High-Risk Screening - 

Toshiyuki Sawa, Japan 

Developing a Framework for Excellence in Lung Cancer Screening – The 

Lung Cancer Alliance Experience – Laurie Fenton-Ambrose, USA 

Lung Cancer – A Health Issue for Women - Stefania Vallone, Italy 

Excellence In Treatment – Exporting Teaching Hospital Standards of 

Care to the Community Hospital Setting - Scott Santarella, USA & 

Danielle Hicks, USA 

14:15 - 15:45 MS 19: Mini Symposium: Global Nursing Issues in Lung Cancer 


Chairs: Patricia Hollen, USA & Beth Ivimey, Australia 

Rooms: 708 + 710 + 712 

 

Nursing Challenges in Clinical Trials - Christel Oyen, Belgium 

50


Screening for Distress, the 6th Vital Sign - Review and Practical 

Implications - Maria Ftanou, USA 

Trends in Oncology Nursing in Japan - Keiko Iino, Japan 

The Importance of Pre- and Early Postoperative Rehabilitation in NSCLC 

patient (Design and Rationale for the PROLUCA Study) - Malene Missel, 

Denmark 

Ethical Challenges in Conducting Clinical Research in Lung Cancer - 

Angela Tod, United Kingdom 

The Lung Cancer Patient - Addressing Issues of Survivorship - Maria 

Guerin, United Kingdom 

14:15 - 15:45 ED 06: Education Session: Treatment of Elderly and High Risk Patients with 

Localized NSCLC 


Chairs: Andrea Ardizzoni, Italy 

Rooms: 702 + 704 + 706 

 

 

 

 

Medical Oncology - Aminah Jatoi, USA 

Radiation Therapy - David Ball, Australia 

Surgery - Michael Weyant, USA 

Pulmonary - Gerard Silvestri, USA 

14:15 - 15:45 ED 07: Education Session: How to Treat Advanced Squamous Carcinoma of the 

Lung 


Chairs: Byoung Chul Cho, South Korea & Primo Lara, USA 


Overview of the Histology and Potential Driver Mutations - Peter 

Hammerman, USA 

Current State of the Art - Glenwood Goss, Canada 

Lung Master Protocol in Squamous Cell Lung Cancer (Lung-MAP, S1400) 

- David R. Gandara, USA 

Targeting Gene Amplification in Squamous Cancer - Paul Paik, USA 

14:15 - 15:45 ED 08: Education Session: Talking with Patients 


Chairs: Luis Alberto Mas Lopez, Peru & Norma Pilnik, Argentina 

Rooms: 108 + 110 + 112 

Transitioning to End of Life Care: Who Should Lead the Discussion? – 

Daniel Handel, USA 

The Art of Taking Care of Patients, The Art of Giving Bad News – Ana 

Oton, USA 

51


Depression, The Silent Killer – Luis Ubillos, Uruguay 

Coping Mechanisms for People with Lung Cancer and their Families - 

Natalie Doyle, United Kingdom 

14:15 - 15:45 ED 09: Education Session: Tissue is the Issue: Improving Diagnostic Yield in the 

Age of Minimally Invasive Procedures 


Chairs: Philip Cagle, USA & Neal Lindeman, USA 


Optimal Biopsy, Challenges - Sanja Dacic, USA 

Difficulties Coordinating Care - Ray Osarogiagbon, USA 

What Do You Do with Tissue Once Collected? What Tests Are Useful? - 

Marileila Varella-Garcia, USA 

Prioritization of Tissue Use - Thomas Hensing, USA 

14:15 - 15:45 Pro Con PC 02: Pro vs Con: Is There a Role for EGFR TKIs in EGFR Mutation 

Negative Disease? 

Track: Treatment of Advanced Disease /Biology, Pathology & Molecular Testing 

Chairs: Sumitra Thongprasert, Thailand & Yi-Long Wu, China 

Rooms: 205 + 207 

 

 

Pro - Scott Laurie, Canada 

Con - Lecia Sequist, USA 

Pro Con PC 02: Pro vs Con: Whole Exome Sequencing vs. Selected Testing (e.g., 

ALK and EGFR) 

Track: Treatment of Advanced Disease /Biology, Pathology & Molecular Testing 

Chairs: Peter Meldgaard, Denmark & Kostas Syrigos, Greece 

Rooms: 205 + 207 

 

 

Pro – Ignacio Wistuba, USA 

Con - Yasushi Yatabe, Japan 




16:45 - 18:15 Oral Session 28: T Cell Therapy for Lung Cancer 


Moderators: Prasad Adusumilli, USA & Egbert Smit, Netherlands 


52


Checkpoint Blockade Augments TCR Engineered Adoptive T Cell Therapy 

for Lung Cancer - Edmund Moon, USA 

Mesothelin-Targeted CAR T-Cell Therapy for the Treatment of 

Heterogeneous Antigen-Expressing Lung Adenocarcinoma - Aurore 

Morello, USA 

Genetic-Engineering Strategies to Enhance CAR T-Cell Therapy Efficacy 

against PD-L1 Expressing Lung Adenocarcinoma and Mesothelioma - 

Leonid Cherkassky, USA 

Tumor-Targeted Radiation Therapy Helps Overcome the Solid Tumor T- 

Cell Infiltration Barrier and Promotes Mesothelin CAR T-Cell Therapy - 

Marissa Mayor, USA 

Mesothelin and MUC16 (CA125) Are Antigen-Targets for CAR T-Cell 

Therapy in Primary and Metastatic Lung Adenocarcinoma - Takashi 

Eguchi, USA 

Discussant - Egbert Smit, Netherlands 

16:45 - 18:15 Oral Session 29: MASCC-IASLC Joint Session: Palliative and Supportive Care 


Moderators: Paul van Houtte, Belgium 

Rooms: 708 + 710 + 712 

 

 

 

 

 

 

Results From Phase III Trials of Anamorelin in Advanced Non-Small Cell 

Lung Cancer Patients with Cachexia: ROMANA 1 and 2 - Amy 

Abernethy, USA 

ONO-7643/Anamorelin for the Treatment of Cancer Cachexia in 

Advanced NSCLC Patients: Results From the Phase 2 Study in Japan - 

Nobuyuki Katakami, Japan 

Efficacy of the Antiemetic Combination Agent, NEPA, in Patients with 

Lung Cancer Receiving Platinum Chemotherapy - Paul Hesketh, USA 

The Impact of Perioperative Immunonutrition on Tissue Healing and 

Infection Related Morbidity in Patients Undergoing Lung Resection for 

NSCLC - Güven Olgaç, Turkey 

Skeletal Muscle and Lean Body Mass Loss Are Associated with Poorer 

Prognosis in Patients with NSCLC Treated with Afatinib - Martha De La 

Torre-Vallejo, Mexico 

Low Prognostic Nutritional Index Correlates with Worse Survival in 

Patients with Advanced NSCLC following EGFR-TKIs - Yunpeng Yang, 

China 

16:45 - 18:15 Oral Session 30: Community Practice 


Moderators: Patricia Kho, Singapore & Robert Jotte, USA 


 

Evolution in the Surgical Care of Non-Small Cell Lung Cancer (NSCLC) 

Patients in the Mid-South Quality of Surgical Resection (MS-QSR) Cohort 

- Edward Robbins, USA 

53


 

 

 

 

 

 

 

Treatment of Non-Small Cell Lung Cancer in Patients with a High 

Comorbidity Index - Jorge Rios, USA 

Access to Cancer Directed Therapies and Cancer Specialists in Patients 

with Metastatic Lung Cancer - Apar Ganti, USA 

Discussant - Stephen Swisher, USA 

Clinical Implementation of the NextDaySeq Lung Panel for Identification 

of Clinically Actionable Variants in Non-Small Cell Lung Cancer - Xiaohua 

Shi, China 

Genomic Analysis of Lung Cancer Tumors from Hispanic Patients Living 

in the US - Luis Raez, USA 

Different Mutation Profiles and Clinical Characteristics Among Hispanic 

Patients with NSCLC Could Explain The "Hispanic Paradox" - María 

Castillo, Mexico 

Discussant - Edward Kim, USA 

16:45 - 18:15 Mini Oral 15: Chemotherapy Developments for Lung Cancer 


Moderators: Lucio Crinò, Italy & Chandra Belani, USA 


 

 

 

 

 

 

 

 

 

 

 

A Phase I/II Study Evaluating the Combination of Resminostat and 

Docetaxel for Platinum-Pretreated NSCLC - Atsushi Horiike, Japan 

NEJ016: Phase II Study of CBDCA and Weekly PTX plus BEV Followed by 

BEV for Highly Selected Elderly Non-Squamous NSCLC Patients - Ou 

Yamaguchi, Japan 

Phase I & II Studies of the Decitabine-Genistein Drug Combination in 

Advanced Solid Tumours - Normand Blais, Canada 

Phase I Study of Continuous Intravenous Infusion of Rh-Endostatin 

Combined with Pemetrexed and Carboplatin in Advanced NSCLC - Yan 

Huang, China 

Discussant - Gilberto Lopes Júnior, Brazil 

Impact of Three and Further Lines in Advanced Non-Small Cell Lung 

Cancer Patients According to Molecular Profile: A Retrospective Analysis 

- Enric Carcereny, Spain 

Prognostic Importance of Pretreatment Sodium Levels in Patients of 

NSCLC Treated with Pemetrexed-Platinum Doublet Chemotherapy - 

Manjunath Nookala Krishnamurthy, India 

A Phase II Study of Pemetrexed plus Carboplatin Followed by 

Maintenance Pemetrexed in Elderly Patients with Advanced Non- 

Squamous NSCLC - Motohiro Tamiya, Japan 

Bayesian Network Meta-Comparison of Maintenance Treatments for 

Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients - Gilberto De 

Lima Lopes, Brazil 

Discussant - Lucio Crinò, Italy 

Optimal Second Line Chemotherapy after 1st Line Pemetrexed and 

Cisplatin Treatment in EGFR Mutation Negative Advanced NSCLC 

Patients - Sung Yong Lee, South Korea 

54


 

 

 

Satisfaction with Therapy and the Relation with Quality of Life in 

Patients with Advanced NSCLC Receiving Chemotherapy - Sabine Visser, 

Netherlands 

An Evaluation of Chemotherapy Regimens in an Unselected Population 

of NSCLC Patients - Stefan Grant, USA 

The Role of Breath Sampling in Monitoring Response to Treatment in 

Lung Cancer - Nir Peled, Israel 

16:45 - 18:15 Mini Oral 16: EGFR Mutant Lung Cancer 2 


Moderators: Gregory Riely, USA & Marina Garassino, Italy 


Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment 

Response in Advanced Non-Small Cell Lung Cancer With Uncommon 

Mutations - Masaki Kanazu, Japan 

Rare and Common EGFR Mutations in Patients with Advanced NSCLC 

Treated with EGFR-TKIs: A Registry-Based Study - Milos Pesek, Czech 

Republic 

Dose Optimization of Rociletinib for EGFR Mutated NSCLC - Jonathan W. 

Goldman, USA 

Activity of Rociletinib in EGFR Mutant NSCLC Patients with a History of 

CNS Involvement - D. Ross Camidge, USA 

Discussant - Caicun Zhou, China 

AZD9291 in Pre-Treated T790M Positive Advanced NSCLC: AURA Study 

Phase II Extension Cohort - James Chih-Hsin Yang, Taiwan 

AZD9291 in Treatment-Naïve EGFRm Advanced NSCLC: AURA First-Line 

Cohort - Suresh Ramalingam, USA 

AZD9291 in Pre-Treated T790M Positive Advanced NSCLC: AURA2 Phase 

II Study - Tetsuya Mitsudomi, Japan 

Design, Execution, and Preliminary Biomarker Results from Paired 

Tumor Biopsy Cohorts of the AZD9291 AURA Trial - Pasi Jänne, USA 

Discussant - Martin Reck, Germany 

Plasma HGF Reduction Is Associated with Better Prognosis in EGFR- 

Positive Advanced Lung Adenocarcinoma Patients Treated with Afatinib 

- Oscar Arrieta Rodriguez, Mexico 

Lung Adenocarcinoma Transformation into Small-Cell Lung Cancer after 

Treatment: Clinical Evidence and the Exploratory Mechanism - Jie 

Wang, China 

A Randomized Controlled Trial of Erlotinib versus Gefitinib in Advanced 

Non-Small-Cell Lung Cancer Harboring EGFR Mutations (CTONG0901) - 

Jin-ji Yang, China 

A Phase 1 Study of Erlotinib and Ruxolitinib in Patients with EGFR- 

Mutant Lung Cancers and Acquired Resistance to Erlotinib Therapy - 

Helena Yu, USA 

Discussant - Trever Bivona, USA 

55


16:45 - 18:15 Mini Oral 17: WT EGFR, Angiogenesis and OMD 


Moderators: Rafal Dziadziuszko, Poland & Ronald Feld, Canada 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Maintenance with Gefitinib/Pemetrexed (G/P) or P After Induction 

P/Platinum for Stage IV Lung Adenocarcinoma with No Sensitizing EGFR 

Mutation - Chun-Ming Tsai, Taiwan 

SWOG 0709: Randomized Phase II Trial of Erlotinib vs. Erlotinib plus 

Carboplatin/Paclitaxel in Patients (Pts) with Advanced Non-Small Cell 

Lung Cancer (NSCLC) and Impaired Performance Status (PS2) as Selected 

by Serum Proteomics - Primo Lara Jr., USA 

Prognostic and Predictive Value of the VeriStrat Classifier in Chemo- 

Naive NSCLC Patients Treated with Erlotinib or Placebo (TOPICAL Trial) - 

Siow-Ming Lee, United Kingdom 

Erlotinib in 2nd Line in Advanced Squamous NSCLC: Final Results of the 

Pepita Cohort - Alain Vergnenegre, France 

Discussant - Ross Soo, Singapore 

Subgroup Analysis of East Asian Patients in the Phase III REVEL Trial - Jin- 

Hyoung Kang, South Korea 

Efficacy of Nintedanib/Docetaxel after Bevacizumab, Pemetrexed or 

Taxanes Therapy - David Heigener, Germany 

Tumor Growth Over Time with Nintedanib/Docetaxel or 

Placebo/Docetaxel in Adenocarcinoma NSCLC: Analysis From the LUME- 

Lung 1 Study - Martin Reck, Germany 

Discussant - Thomas John, Australia 

Oligometastatic Non-Small-Cell Lung Cancer and Unresectable Primary 

Tumor: Safety and Efficacy of Radical Treatment - Javier Garde- 

Noguera, Spain 

Results of Radical Local Treatment of Non-Small Cell Lung Cancer 

Patients with One or Two Synchronous Metastases - Margriet Kwint, 

Netherlands 

Survival Analysis of Stage IV NSCLC with Synchronous Isolated 

Metastasis in a Large Retrospective Cohort - Anne Claire Toffart, France 

Prognosis of Stage III NSCLC Patients Presenting with Isolated Brain 

Failure after Definitive Concurrent Chemoradiotherapy - Erkan Topkan, 

Turkey 

Survival Analysis following Pulmonary Metastasectomy for Non-Small 

Cell Lung Cancer - Hyo-Jun Jang, South Korea 

Discussant - Melissa Johnson, USA 

16:45 - 18:15 Mini Oral 18: Radiation Topics in Localized NSCLC 


Moderators: David Raben, USA & Sue Yom, USA 

Rooms: 601 + 603 

56


 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stereotactic Body Radiation v. Observation for Early-Stage NSCLC in 

Elderly Patients - Ronica Nanda, USA 

Stereotactic Body Radiotherapy Is Safe and Effective in Octo- and 

Nonagenarians for the Treatment of Early Stage Lung Cancer - Heike 

Peulen, Netherlands 

Immune Activation in Early Stage Non-Small Cell Lung Cancer (NSCLC) 

following Stereotactic Ablative Radiotherapy (SABR) and Surgery - 

Joachim Aerts, Netherlands 

Tumor Volume Variations and Related Dosimetric Impact During 

Stereotactic Body Radiation Therapy for Lung Cancer - Luigi Moretti, 

Belgium 

Discussant - Hak Choy, USA 

Validation of High Risk Features on CT for Detection of Local Recurrence 

After SBRT for Stage I NSCLC - Heike Peulen, Netherlands 

Early Results of a Quality Assurance Program in a Randomized Trial of 

Stereotactic Body Radiotherapy for Stage I Medically Inoperable Lung 

Cancer - Anand Swaminath, Canada 

A Systematic Review of Comparative Effectiveness Studies of Surgery 

versus SABR in Early Stage Lung Cancer: How Good Is the Data? - 

Alexander Louie, Canada 

Survival of Elderly Patients after SABR for Early Lung Cancers - A 

Population Based Retrospective Comparison of Survival among Age 

Cohorts - Devin Schellenberg, Canada 

Does Motion Management Technique for Lung SBRT Influence Local 

Control? - Gregory Videtic, USA 

Assessment of Dose Response via Regional Lung Perfusion following 

Stereotactic Radiotherapy for Lung Cancer - Ross McGurk, USA 

Can Stereotactic Ablative Radiotherapy (SABR) Improve Patient 

Selection for Lung Cancer Surgery and Reduce Perioperative Mortality? - 

Drew Moghanaki, USA 

Pre-Existing Pulmonary Fibrosis Increases the Risk of Radiation 

Pneumonitis - Sorcha Campbell, United Kingdom 

Discussant - Wilfried Eberhardt, Germany 

16:45 - 18:15 Mini Oral 19: Surgical Topics in Localized NSCLC 


Moderators: David Jablons, USA & Brendon Stiles, USA 

Rooms: 605 + 607 

 

 

 

Benefits of Surgical Treatment and Complementary Utility of Metabolic 

Tumor Volume in Selecting Therapy for Stage III NSCLC - Yonglin Pu, 

USA 

Mediastinal Nodal Involvement in Patients with Clinical Stage I Non- 

Small-Cell Lung Cancer -Possibility of Rational Lymph Node Dissection- - 

Tomohiro Haruki, Japan 

Subcarinal Lymph Node Dissection Is Also Necessary in Upper 

Lobectomies for Lung Cancer - Jens Eckardt, Denmark 

57


 

 

 

 

 

 

 

 

 

 

 

Relationship Between Adequacy of Intra-Operative Lymph Node 

Sampling During Surgical Resection of NSCLC and Survival - Richard 

Booton, United Kingdom 

Discussant – Michael Weyant, USA 

External Validation of a Chinese Developed Survival Score in a Western 

Cohort Undergoing Surgery for Non-Small Cell Lung Cancer - Ulas 

Kumbasar, United Kingdom 

ICG Fluorescence Localization of Small Sized Pulmonary Nodules for 

VATS - Takashi Anayama, Japan 

Validation of a Surgical Predictive Score for 90 Day Mortality in Lung 

Cancer and Comparison with Thoracoscore - Emma O'Dowd, United 

Kingdom 

Adjunct Intraop Cone Bean CT (CBCT) with Real Time 3D Overlay 

Improves Diagnostic Accuracy of Electromagnetic Navigational 

Bronchoscopy (ENB) - Sandeep Sachidananda, USA 

Use of Electromagnetic Navigational Bronchoscopy to Localize 

Pulmonary Nodules Prior to Minimally Invasive Sublobar Resection - 

Sandeep Sachidananda, USA 

The Value of Video-Assisted Mediastinoscopic Lymphadenectomy in 

Clinical Stage I Non-Small Cell Lung Cancers - Akif Turna, Turkey 

Nodal Staging via Robotic-Assisted Thoracic Surgery for Clinical Stage I 

Non-Small Cell Lung Cancer - Vanessa Dipasquale, USA 

Survival After Sub-Lobar Resection for Early Stage Lung Cancer: 

Methodological Obstacles in Comparing the Efficacy to Lobectomy - 

Emanuela Taioli, USA 

Discussant - Jesper Pedersen, Denmark 

16:45 - 18:15 Mini Oral 20: Surgery 


Moderator: Giulia Veronesi, Italy 

Rooms: 201 + 203 

 

 

 

 

 

 

Do Secondary Lung Cancers Have the Same Disease-Specific Survival and 

Overall Survival as Primary Lung Cancers? - Cameron Stock, USA 

Risk-Adjusted Margin Positivity (RAMP) Rate as a Surgical Quality Metric 

for Non-Small-Cell Lung Cancer in the US National Cancer Data Base 

(NCDB) - Chun Chieh Lin, USA 

The Survival Impact of Missed Lymph Node Metastasis in Surgically 

Resected Non-Small Cell Lung Cancer (NSCLC) - Nicholas Faris, USA 

Right-Sided vs Left-Sided Pneumonectomy after Induction Therapy for 

Non-Small Cell Lung Cancer - Chi-Fu Yang, USA 

Discussant - Ugo Pastorino, Italy 

The Importance of Sleeve Lobectomy after Induction Therapy for 

Patients with Stage IIIA-N2 Lung Cancer: The Avoidance of 

Pneumonectomy - Jong Ho Cho, South Korea 

58


 

 

 

 

 

 

 

 

Extended Cervical Mediastinoscopy (ECM) for Biopsy of AortoPulmonary 

Window (APW) Lymph Nodes and an APW Index (APWI) Useful in 

Patient Selection - Robert Cameron, USA 

Survival in Unexpected Multi-Station pN2 Following Surgical Resection 

of NSCLC - Richard Booton, United Kingdom 

Discussant – Valerie Rusch, USA 

Prognostic Impact of Lymph Node Ratio in Patients with Pathologic 

Stage N1 Non-Small Cell Lung Cancer - Sumin Shin, South Korea 

Lymph Node Impact on Conversion of VATs Lobectomy to Open 

Thoractomy - Yun Li, China 

Advancements in Bronchoplasty as Treatments for Lung Cancer: Single 

Institutional Review of 213 Patients - Takeshi Nagayasu, Japan 

A Prospective Comparison of FDG-PET & EBUS for Determining the 

Extent of Mediastinal Lymph Node Involvement in NSCLC - Daniel 

Steinfort, Australia 

Discussant - Gail Darling, Canada 

16:45 - 18:15 Mini Oral 21: Novel Targets 


Moderators: Benjamin Levy, USA & Daniel Shao Weng Tan, Singapore 


 

 

 

 

 

 

 

 

 

 

 

 

Purinergic Signaling in NSCLC - First in Vivo Data and Potential 

Therapeutic Targets - Severin Schmid, Germany 

CCT68127 Is a next Generation CDK2/9 Inhibitor with Potent 

Antineoplastic Activity Against Lung Cancer Cells - Masanori Kawakami, 

USA 

CACNA2D1 Is a Novel Biomarker for Tumor Initiating Cells and Has 

Therapeutic Effect in Non-Small Cell Lung Cancer - Yuanyuan Ma, China 

HS3ST3B1 Is a Novel Regulator of TGF-Beta Mediated EMT and 

Regulated by miR-218 in Lung Cancer - Yongsheng Wang, China 

Discussant - Sanjay Popat, United Kingdom 

Role of the Focal Adhesion Protein Paxillin in Lung Cancer - From 

Genetic Alterations to Novel Mitochondrial Functionality - Rifat Hasina, 

USA 

Oncogenic EZH2 Is an Actionable Target in Patients with 

Adenocarcinoma of the Lung (LUAD) - George Simon, USA 

Bombesin Receptor Subtype-3: An Underappreciated Growth Factor in 

Lung Cancer - Paola Moreno, USA 

Discussant - Jin Soo Lee, South Korea 

The TORK/DNA-PK Inhibitor CC-115 Shows Combination Anti- 

Proliferative Effects with Erlotinib in NSCLC Cells Resistant to EGFR 

Inhibition - Simon Ekman, USA 

A Novel Cell Line Model of EGFR Exon 20 Insertion Mutations - Adriana 

Estrada-Bernal, USA 

Identification of a First in Class TWIST1 Inhibitor with Activity in KRAS 

Mutant NSCLC - Timothy Burns, USA 

59


 

Discussant - Giuseppe Giaccone, USA 

16:45 - 18:15 Mini Oral 22: New Technology 


Moderators: Lauren Byers, USA & Yasushi Yatabe, Japan 

Rooms: 205 + 207 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Detecting ALK, ROS1 and RET Fusion Genes in Advanced Non-Small Cell 

Lung Cancer (NSCLC) Using a Novel Multiplexed NCounter-Based Assay - 

Noemi Reguart, Spain 

Clinically Adoption of MSK-IMPACT, a Hybridization Capture-Based next 

Generation Sequencing Assay, for the Assessment of Lung 

Adenocarcinomas - Maria Arcila, USA 

Next Generation Immunohistochemical Stains; True Multiplex 

(Quadruple) Immunohistochemical Panel for Non-Small Cell Lung 

Carcinoma - Charalambos Solomides, USA 

Discussant - Johan Botling, Sweden 

Quality Control Process for NGS to Minimize False Positives - Carl 

Morrison, USA 

The Challenge of Molecular Testing for Clinical Trials in Advanced Non- 

Small Cell Lung Cancer Patients: Analysis of a Prospective Database - 

Stefanie Lepers, Belgium 

An in Vitro Biomimetic Multi-Organ Microfluidic Chip System to Test 

Lung Cancer Metastasis - Qi Wang, China 

Development of a Protein Viewer for Displaying Variants of Unknown 

Significance in Relation to Actionable Mutations and Protein Domains - 

Antonios Papanicolau-Sengos, USA 

Discussant - Peter Mazzone, USA 

A New Approach to Large Scale Proteomic Profiling to Uncover Tumor 

Phenotypes - Rachel Ostroff, USA 

A Clinical Platform for Examining Mechanism-Driven Chemotherapeutic 

Agents - Cherie Erkmen, USA 

Nanotechnology for the Treatment of Lung Cancer: The Future of 

Targeted Therapy - Gannu Praveen Kumar, India 

Molecular Characterisation of SCLC Using Both Circulating Tumour DNA 

and Circulating Tumour Cells Isolated from the Same Whole Blood 

Sample - Dominic Rothwell, United Kingdom 

Discussant - Eric Haura, USA 

16:45 - 18:15 Mini Oral 23: Lung Cancer Risk: Genetic Susceptibility and Airway Biology 


Moderators: Pieter E. Postmus, Netherlands & Robert Young, New Zealand 

Rooms: 401 - 404 

 

Risk of Lung Cancer in Female Non-Smokers Requires Extended 

Screening Guidelines - Michael Jaklitsch, USA 

60


 

 

 

 

 

 

 

 

 

 

 

 

 

 

COPD Severity by GOLD Status and Lung Cancer Risk: Results from a 

Large Prospective Screening Study (NLST-ACRIN Cohort Analysis, N=18, 

714) - Raewyn Hopkins, New Zealand 

Targeted Exome Sequencing of Smokers Susceptible and Resistant to 

Chronic Obstructive Pulmonary Disease - Yanhong Liu, USA 

Familial Clustering of Lung Cancer (LC) Cases in a South European 

Population (sEp) - Ignacio Gil-Bazo, Spain 

A Case-Control Study on the Genetic Risks for Development of Lung 

Adenocarcinoma in Never-Smoking Hong Kong Population - Li Han, 

Hong Kong 

Discussant - York Miller, USA 

The Airway Field of Injury Reflects Metabolic Changes Associated with 

the Presence of Lung Squamous Premalignant Lesions - Sarah Mazzilli, 

USA 

Comparison of in Vivo Raman and NIR Spectroscopy and EBUS as 

Confirmatory Method for Ideal Biopsy Area during Bronchoscopic 

Navigation - Jiri Votruba, Czech Republic 

Clinical Application of Computer Assistant Diagnostic System in Probe- 

Based Confocal Laser Endomicroscopy (pCLE) for Pulmonary Diseases - 

Dawei Yang, China 

Subtraction of Allelic Fractions (Delta- θ): A Sensitive Metric to Detect 

Chromosomal Alterations in Heterogeneous Premalignant Specimens - 

Ichiro Nakachi, Japan 

Discussant - Luc Thiberville, France 

HAases and HAS in Lung/Bronchial Pre-Neoplastic Lesions: Impact on 

Prognosis - Vanessa De Sá, Brazil 

Extracellular Sulfatase SULF2: A Potential Biomarker for the Early 

Detection of Lung Cancer - Hassan Lemjabbar-Alaoui, USA 

Circulating Long Non-Coding RNA GAS5 Is a Novel Biomarkers for the 

Diagnosis of Non-Small Cell Lung Cancer - Yong Song, China 

Discussant - Céline Mascaux, France 

16:45 - 18:15 Mini Oral 24: Epidemiology, Early Detection, Biology 


Moderators: Jenette Creaney, Australia & Michele Carbone, USA 

Rooms: 102 + 104 + 106 

Pleural and Peritoneal Malignant Mesothelioma in Women Correlated 

to Occupational, Domestic and Environmental Asbestos Exposure - 

Vasiliki Panou, Denmark 

Mesothelioma Risk in Turkey - Muzaffer Metintas, Turkey 

Asbestos Knowledge and Awareness Level - Selma Metintas, Turkey 

Cluster Analysis of Malignant Mesothelioma Incidence in Louisiana - 

Elizabeth Levitzky, USA 

Discussant - Marjorie Zauderer, USA 

Mesothelioma in Finland: 10 Year Population-Based Cohort Between 

2000-2009 - Ilkka Ilonen, Finland 

61


 

 

 

 

 

 

 

 

 

Infrared Spectroscopy as a Novel Approach in Differential Diagnosis of 

Malignant Pleural Mesothelioma from Lung Cancer Using Pleural Fluid - 

Salih Emri, Turkey 

Breath Analysis by Ion Mobility Spectrometry Allows Discrimination of 

Pleural Mesothelioma Patients From Controls - Kevin Lamote, Belgium 

Cell-Free MicroRNA miR-625-3p Is Elevated in the Blood of Patients with 

Thoracic Malignancies - Michaela Kirschner, Australia 

Discussant - Takashi Nakano, Japan 

Expression of PD-1 and Its Ligands in Human Malignant Pleural 

Mesothelioma - Elly Marcq, Belgium 

Assessment of PD-L1, TGF-β Expression and Tumor-Infiltrating CD8+ T 

Cells in Advanced Thymic Epithelial Tumors - Jie Wang, China 

Molecular and Pathological Features of Different Malignant Pleural 

Mesothelioma (MPM) Histologic Subtypes - Giulia Pasello, Italy 

Use of Next Generation Sequencing to Improve Lung Tumor 

Immunotherapy - Bruce Robinson, Australia 

Discussant - Enriqueta Felip, Spain 

16:45 - 18:15 Mini Oral 25: Trials, Radiation and Other 


Moderators: Jose Clavero, Chile & Raffit Hassan, USA 

Rooms: 702 + 704 + 706 

A Phase II Study of Dovitinib in Previously-Treated Malignant Pleural 

Mesothelioma: The Ontario Clinical Oncology Group DOVE-M Trial - 

Scott Laurie, Canada 

A Clinical Study on Intra-Thoracic Chemotherapy of Recombinant 

Human Endostatin Combined with Cisplatin for Malignant Pleural 

Effusion - Xingsheng Hu, China 

Potent Anti-Mesothelioma Activity by the Novel Naftopidil Analogue 

HUHS1015; Preclinical Evidence for Treatment - Kozo Kuribayashi, 

Japan 

Utilizing Molecular Profiling to Identify Potential Therapies in 

Sarcomatoid Lung Cancer - Panagiotis Fidias, USA 

Discussant - Anne Tsao, USA 

Appropriate Time of Adjuvantr Adiotherapy for Thymoma with MG After 

Thymectomy - Lei Yu, China 

Clinical Activity of Lucitanib in Advanced Thymic Epithelial Tumours - 

Benjamin Besse, France 

Systemic Treatment in Advanced Thymic Epithelial Tumors. Insights 

From a Prospective Cohort of 888 Patients Enrolled in RYTHMIC - 

Nicolas Girard, France 

Percutaneous Cryoablation for Recurrent Mesothelioma following Lung 

Sparing Pleurectomy and Decortication: Safety and Efficacy - Fereidoun 

Abtin, USA 

Discussant - Francoise Mornex, France 

62


 

 

 

 

 

Optimization of Gross Tumour Volume Definition in Lung-Sparing 

Volumetric Modulated Arc Therapy for Pleural Mesothelioma - Dirk De 

Ruysscher, Belgium 

Hospital Resource Utilization and Outcomes of Pleurectomy Compared 

to Extrapleural Pneumonectomy for Mesothelioma - Robert Cameron, 

USA 

Survival Prediction Model of Repeated Pulmonary Metastasectomy for 

Osteosarcoma: A Nomogram and Regression Trees - Haewon Lee, South 

Korea 

Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia 

(DIPNECH): Descriptive Analysis and Overall Survival - Mukesh Kumar, 

USA 

Discussant - John Edwards, United Kingdom 

18:30 - 20:00 Symposium supported by Boehringer Ingelheim: Individual EGFR Mutations: 

Informing First-Line Treatment in EGFR Mutation-Positive NSCLC 

Chair: Ramaswamy Govindan, USA 

Rooms: 205 + 207 

 

 

 

 

 

Welcome and Introductions - Ramaswamy Govindan, USA 

The Role of Biomarker Testing in Advanced NSCLC - Shirish Gadgeel, 

USA 

ErbB Family Blockade in EGFR mutation-positive NSCLC - David Carbone, 

USA 

First-Line Treatment of EGFR Mutation-Positive NSCLC: Patient Case 

Study - Panos Fidias, USA 

Final Questions and Meeting Close - Ramaswamy Govindan, USA 

*Agenda: click here 

20:00 - 23:00 Gala Dinner (Ticketed Event) 

Room: Hall A 

63

Wednesday, September 9, 2015 


07:00 - 08:00 Symposium supported by AstraZeneca Pharmaceuticals LP, Bristol-Myers 

Squibb Company and Genentech BioOncology: The Current and Emerging Role 

of Immune Checkpoint Inhibitors in the Management of Lung Cancer 

Rooms: 401 - 404 

 

Website: 

www.researchtopractice.com/Meetings/IASLC2015/Immunotherapy 

07:00 - 08:00 Symposium supported by Boehringer Ingelheim Pharmaceuticals Inc.: ERBB 

Family Blockade in NSCLC: Expert Perspectives on Optimizing Management 

Chair: Barbara Gitlitz, USA 

Rooms: 601 + 603 

Website: www.ecgcme.com/erbb 

 

 

 

 

EGFR Testing and ERBB Family Members/Inhibitors - Geoffrey Oxnard 

Critical Updates on EGFR-TKIs in Selected Populations - Anne Tsao 

Addressing the Challenge of Acquired Resistance to EGFR TKIs - Helena 

Yu 

Thoughts From the Chair - Barbara Gitlitz 

07:00 - 08:00 Highlights of the Previous Day HOD 03: Treatment of Advanced, Localized and 

LocoRegional Disease and Small Cell, Thymoma, Mesothelioma 

Track: Highlights from Tuesday, September 8 


 

 

 

 

Treatment of Advanced Disease - Luis Paz-Ares, Spain 

Treatment of Localized Disease - Mark Kris, USA 

Treatment of LocoRegional Disease - Ronald Natale, USA 

Small Cell/Thymoma/Mesothelioma/Other - Martin Edelman, USA 

07:00 - 08:00 Highlights of the Previous Day HOD 04: Biology, Pathology, Molecular Testing, 

Prevention, Tobacco Control, Screening and Early Detection 

Track: Highlights from Tuesday, September 8 


 

 

 

Biology, Pathology, Molecular Testing - Philip Cagle, USA 

Prevention, Tobacco Control - Silvia Novello, Italy 

Screening, Early Detection - Pieter E. Postmus, Netherlands 

07:00 - 08:00 MTE 23: Meet the Expert: Standard Therapy for Advanced NSCLC in Absence of 

Driver Mutations (Ticketed Session) 

64



Speaker: Corey Langer, USA 

Room: 103 

07:00 - 08:00 MTE 24: Meet the Expert: Rising to the Challenge of Testing Small Biopsy 

Specimens (Ticketed Session) 


Speaker: Lynette Sholl, USA 

Room: 105 

07:00 - 08:00 MTE 25: Meet the Expert: New Therapies for Squamous Cell Carcinoma 



Speaker: Shirish Gadgeel, USA 

Room: 107 

07:00 - 08:00 MTE 26: Meet the Expert: Multidisciplinary Approach to a Comprehensive CT 

Screening Program (Ticketed Session) 


Speaker: David Midthun, USA 

Room: 109 

07:00 - 08:00 MTE 27: Meet the Expert: Modern Approaches to Radiotherapy in Stage III 

Disease (Ticketed Session) 


Speaker: Maria Werner-Wasik, USA 

Room: 111 

07:00 - 08:00 MTE 28: Meet the Expert: Need for Team Building in Caring for Patients with 

Thoracic Malignancies (Ticketed Session) 


Speaker: Melissa Culligan, USA & Richard Gralla, USA 

Room: 102 + 104 + 106 

07:00 - 08:00 MTE 29: Meet the Expert: Managing Side Effects from Tyrosine Kinase 

Inhibitors (Ticketed Session) 


Speaker: Anne Fraser, New Zealand 

Room: 108 + 110 + 112 

65


07:00 - 08:00 MTE 30: Meet the Expert: Cachexia (Ticketed Session) 


Speakers: Amy Abernethy, USA & Jeffrey Crawford, USA 

Room: 702 + 704 + 706 

07:00 - 08:00 MTE 31: Meet the Expert: Smoking Cessation Integrated with Screening 

(Window of Opportunity) (Ticketed Session) 


Speakers: Denise Aberle, USA & Jamie Ostroff, USA 

Room: 708 + 710 + 712 

07:00 - 08:00 MTE 32: Meet the Expert: Treatment of Early Stage SCLC (Ticketed Session) 


Speakers: Jacek Jassem, Poland & Eric Lim, United Kingdom 

Room: 703 

07:00 - 08:00 MTE 33: Meet the Expert: (Debate on) Prognostic Biomarkers in Mesothelioma 



Speakers: Raphael Bueno, USA & Bruce Robinson, Australia 

Room: 201 + 203 

08:15 - 09:45 Plen 03: Plenary Session: Science Drives Lung Cancer Advances 


Chairs: Tetsuya Mitsudomi, Japan & Tony Mok, Hong Kong 


 

 

 

 

 

Lung Cancer Genomes - Adenocarcinoma - Matthew Meyerson, USA 

Lung Cancer Genomes - Squamous Cell Carcinoma/Small Cell - Roman 

Thomas, Germany 

Molecular Mechanisms of Drug Resistance - Pasi Janne, USA 

Personalized Medicine - Jean-Charles Soria, France 

Mouse Models of SCLC and NSCLC - Anton Berns, Netherlands 


Moderator: Dr. Paul A. Bunn, Jr., Distinguished Professor of Medicine at the 

University of Colorado Denver School of Medicine 

Room: 108 + 110 + 112 

66


Daily Theme: Science Drives Lung Cancer Advances - Dr. David R. 

Gandara, Professor of Medicine, Division of Hematology/Oncology, 

Director, Thoracic Oncology Program, Senior Advisor to the Director, 

UC Davis Comprehensive Cancer Center, Sacramento, California 

Abstract – Randomized Phase III Trial of Adjuvant Chemotherapy with or 

without Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC): 

Results of E1505 - Dr. Heather Wakelee, Associate Professor of 

Medicine (Oncology) at the Stanford University Medical Center, 

Stanford, California 

Abstract – Stopping Smoking Reduces Mortality in Low-Dose Computed 

Tomography (LDCT) Screening Volunteers - Dr. Ugo Pastorino, Director 

Thoracic Surgery, IRCCS Istituto Nazionale dei Tumori Foundation, 

Milan, Italy 

Abstract – Multiregion Whole Exome and Transcriptome Sequencing 

Defines the Genomic Spectrum of EGFR+ NSCLC and Reveals Novel 

Mechanisms of TKI Resistance - Dr. Daniel Shao Weng Tan, Consultant, 

Medical Oncology, National Cancer Centre, Singapore 

Abstract – A Randomized, Phase III Study Comparing 

Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or 

without Concurrent Cetuximab in Patients with Advanced Non-Small 

Cell Lung Cancer (NSCLC): SWOG S0819 - Dr. Roy Herbst, Ensign 

Professor of Medicine, Professor of Pharmacology, Chief of Medical 

Oncology, Director, Thoracic Oncology Research Program, Associate 

Director for Translational Research, Yale Comprehensive Cancer 

Center, Yale School of Medicine, New Haven, Connecticut 

Abstract – EGFR IHC and FISH Correlative Analyses (SQUIRE Trial): 

Necitumumab + Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin in 1st- 

Line Squamous NSCLC - Dr. Fred R. Hirsch, IASLC CEO, Congress 

President, Professor of Medicine and Pathology, University of 

Colorado 

Q & A 




10:45 - 12:15 Plen 04: Presidential Symposium incl. Top 4 Abstracts 


Chairs: Tony Mok, Hong Kong & Fred R. Hirsch, USA 


A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or 

Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent 

Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer 

(NSCLC): SWOG S0819 - Roy Herbst, USA 

67


 

 

 

 

 

 

 

Discussant – Robert Pirker, Austria 

Randomized Phase III Trial of Adjuvant Chemotherapy with or without 

Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC): Results 

of E1505- Heather Wakelee, USA 

Discussant - Paul A. Bunn, Jr, USA 

Multiregion Whole Exome and Transcriptome Sequencing Defines the 

Genomic Spectrum of EGFR+ NSCLC and Reveals Novel Mechanisms of 

TKI Resistance - Daniel Shao Weng Tan, Singapore 

Discussant - Roman Thomas, Germany 

Stopping Smoking Reduces Mortality in Low-Dose Computed 

Tomography (LDCT) Screening Volunteers - Ugo Pastorino, Italy 

Discussant - Nise Yamaguchi, Brazil 

12:30 - 14:00 Symposium supported by Astellas Scientific and Medical Affairs Inc, 

AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, 

Foundation Medicine, Genentech BioOncology and Novartis Pharmaceuticals 

Corporation: Targeted Treatment of Non-Small Cell Lung Cancer: Current 

Algorithms and New Agents 


 

Website: www.researchtopractice.com/Meetings/IASLC2015/Mutations 

14:15 - 15:45 GR 03: Grand Rounds: Extensive Small Cell with Excellent Response to 1st Line 

Rx (PCI, Chest and/or Oligomet RT) and Second Line / Treatment of Thymic 

Malignancies 

Track: Small Cell Lung Cancer / Thymoma, Mesothelioma and Other Thoracic 

Malignancies 

Chairs: Bruce Johnson, USA & Brian Kavanagh, USA / Paris Kosmidis, Greece & 

Enrico Ruffini, Italy 

Rooms: 102 + 104 + 106 

 

 

 

 

 

 

 

 

Part 1: Extensive Small Cell with Excellent Response to 1st Line Rx (PCI, 

Chest and/or Oligomet RT) and Second Line 

SCLC Therapy - Ritsuko Komaki, USA 

Systemic Therapy of Extensive Stage Small Cell Lung Cancer (SCLC): 

Contrasting Therapeutic Principles for SCLC and Non-small Cell Lung 

Cancer (NSCLC) in 2015 - Nevin Murray, Canada 

Part 2: Treatment of Thymic Malignancies 

Surgery - Frank Detterbeck, USA 

Radiotherapy - Daniel Gomez, USA 

Biology and Standard Treatment - Giuseppe Giaccone, USA 

Thymic Epithelial Tumors: New Hope on the Horizon with Novel 

Therapeutic Strategies - Benjamin Besse, France 

14:15 - 15:45 GR 04: Grand Rounds: Problems in Advanced Metastatic Disease 

68



Chairs: Karen Kelly, USA & Robert Pirker, Austria 

Rooms: 702 + 704 + 706 

 

 

 

 

Case of a Patient with EGFR Mutation Positive Disease and Two Small 

Brain Metastases - Corinne Faivre-Finn, United Kingdom 

Leptomeningeal Carcinomatosis - Ross Soo, Singapore 

Systemic Treatment with Organ Failure - Paul Wheatley-Price, Canada 

A Case of Recurrent Clotting in Lung Cancer Despite Initial 

Anticoagulation - Rachel Rosovsky, United States 

14:15 - 15:45 MS 20: Mini Symposium: Joint Imaging/Therapy Conference 


Chairs: Odd Terje Brustugun, Norway & Dominique Grunenwald, France 

Rooms: 601 + 603 

 

 

 

 

Imaging for Surgical Treatment Decision and Planning - Hans Hoffmann, 

Germany 

Imaging for Radiation Therapy Planning - Jeffrey Bogart, USA 

Optimal Monitoring after Combined Modality Treatment (Imaging and 

Markers) - Michael MacManus, Australia 

Prevention, Diagnosis and Treatment of Radiation Pneumonitis - Laurie 

Gaspar, USA 

14:15 - 15:45 MS 21: Mini Symposium: Immunotherapy Predictive Biomarkers 


Chairs: Kwun Fong, Australia & Philip Dennis, USA 


 

 

 

 

Overview of Immunotherapy - Julie Brahmer, USA 

PD1/PDL1 Biomarker Strategies - Elisabeth Brambilla, France 

Assessment of Immune Cells in Tumor Biopsies as a Biomarker - Ignacio 

Wistuba, USA 

Search for Genetic/Molecular Predictors of Immune Checkpoint Therapy 

- Role of KRAS, LKB1, Other Genetic Markers as Predictors for 

Immunotherapy - Scott Gettinger, USA 

14:15 - 15:45 MS 22: Mini Symposium: Variety in the Oncogene (Does the Exact Mutation 

Matter?) 


Chairs: Robert Doebele, USA & Giorgio Scagliotti, Italy 


 

EGFR Mutations (e.g., Exon 18 vs. 19 vs. 20 vs. 21) - Daniel Costa, USA 

69


 

 

 

ALK, ROS1, and RET – Does the Partner Gene Matter? - Christine Lovly, 

USA 

MET - Gene Amplification vs. Overexpression vs. Exon 14 Skipping - Ravi 

Salgia, USA 

KRAS – Are All KRAS Mutations the Same? - Thomas Stinchcombe, USA 

14:15 - 15:45 MS 23: Mini Symposium: Risk Factors: Beyond the Cigarette 


Chairs: Nise Yamaguchi, Brazil 

Rooms: 605 + 607 

Radon and Lung Cancer - Boris Melloni, France 

Air Pollution-Outdoor; Biomass Smoke; Cooking Fuels - Paolo Boffetta, 

USA 

Legalization of Marijuana: Implication for Lung Health - James Jett, USA 

Other Tobacco Products Electronic Devices/Water Pipes/Hookas - 

Elizabeth Durmowicz, USA 

Cost Efficacy of Tobacco Cessation Versus Treatment of Lung Cancer - 

William K Evans, Canada 

14:15 - 15:45 MS 24: Mini Symposium: CT Screening: Minimize Harm/Cost and Risk 

Assessment 


Chairs: David Midthun, USA & Jesper Pedersen, Denmark 


Definition of Positive Cases and False Positives - David Yankelevitz, USA 

Computer Assisted Lung Cancer Screening: Automated CT Image 

Analysis - Anthony Reeves, USA 

Role of PET Scan in Workup of Nodules - Ugo Pastorino, Italy 

Biomarkers in Selection for CT Screening/Management of Nodules - 

Harvey Pass, USA 

14:15 - 15:45 MS 25: Mini Symposium: Lung Carcinogenesis 


Chairs: Wilbur Franklin, USA & Harubumi Kato, Japan 

Rooms: Mile High Ballroom 2a - 3b 

 

 

 

 

 

Early Airway Disease - Sam Janes, United Kingdom 

Transcriptional Profiling of Malignant Lesions - Brigitte Gomperts, USA 

Peripheral Premalignancy - Ming Tsao, Canada 

Molecular Pathology of Alveolar Premalignancy - Masayuki Noguchi, 

Japan 

Premalignant Lesions: Cytokines and Microenvironment - Steven 

Dubinett, USA 

70


14:15 - 15:45 MS 26: Mini Symposium: Genomic Alterations and Drug Targets 

Track: Small Cell Lung Cancer / Biology, Pathology & Molecular Testing 

Chairs: David Beer, USA & Jonathan Goldman, USA 


 

 

 

 

 

Genomic Alterations - James Yang, Taiwan 

The MYC/MAX and the SWI/SNF Networks: Biological Understanding 

and Therapeutic Applications - Montse Sanchez-cespedes, Spain 

Targeting ASCL1 in Neuroendocrine Lung Cancers via a MAPK-Regulated 

Double-Negative Feedback Loop - John Minna, USA 

FGFR1 Co-Activation Networks in Lung Cancer - Lynn Heasley, USA 

Drug Screening Targets - Christine Lee Hann, USA 

14:15 - 15:45 MS 27: Mini Symposium: Advocacy in Practice 


Chairs: Tommy Bjork, Sweden & Aoife McNamara, Ireland 

Room: 703 

Influencing Clinical Trials to Meet Patients’ Needs and End-Points – 

Involving the Patient from the Neginning - Dickran Kazandjian, USA 

Incorporating Quality of Life & Palliative Care Measures in Clinical Trial 

Designs - Raphael Catane, Israel 

Let’s Yarn About Lung Cancer - An Indigenous Community Project in 

Regional Australia – Kerrie Callaghan, Australia 

Supporting Lung Cancer Survivors – Living with and Beyond Lung Cancer 

- Janet Freeman-Daily, USA 

14:15 - 15:45 MS 28: Mini Symposium: Future Clinical Trials 

Track: Other 

Chairs: Mary Redman, USA & Sumithra Mandrekar, USA 

Rooms: 205 + 207 

 

 

 

 

Trial Designs - Mary Redman, USA 

Master Protocols - Shakun Malik, USA 

Biomarkers - Fred R. Hirsch, USA 

Drug Development and Drug Approval- Richard Gaynor, USA 

14:15 - 15:45 ED 10: Education Session: Controversies in Stage IIIA Disease 


Chairs: Chandra Belani, USA & Everett Vokes, USA 

Rooms: 201 + 203 

71


 

 

 

 

Staging and Decision Making in Patient Selection-Surgery - Kenji Suzuki, 

Japan 

Multiple Modality Choices: Combinations, Sequences, Subsets - Kathy 

Albain, USA 

Induction Chemotherapy as an Investigational Strategy - Wilfried 

Eberhardt, Germany 

Case Presentation - Kemp Kernstine, USA 

14:15 - 15:45 ED 11: Education Session: Extending Personalized Treatment Beyond EGFR 


Chairs: Roman Perez-Soler, USA & Ross Camidge, USA 

Rooms: 401 - 404 

 

 

 

 

What Testing is Needed for Clinical Treatment? - Paul A. Bunn, Jr, USA 

Communicating with Pathologists About Molecular Testing - Cesar 

Octavio Lara-Torres, Mexico 

1st Line and Beyond for ALK, ROS-1, BRAF, RET, FGFR Positive Lung 

Cancer - David Spigel, USA 

Prioritizing New Agents When More Than One Is Available and 

Combining Targeted Agents - Ross Camidge, United States 

14:15 - 15:45 ED 12: Education Session: Caring for the Lung Cancer Patient 


Chairs: Anne Fraser, New Zealand & Michelle Turner, USA 

Rooms: 108 + 110 + 112 

 

 

 

 

 

 

Management of Paraneoplastic Syndrome - John White, United 

Kingdom 

Addressing the Nutritional Needs of the Lung Cancer Patient - Melissa 

Culligan, USA 

Navigating Care for the Lung Cancer Patient - Vanessa Beattie, United 

Kingdom 

The Role of the Occupational Therapist in the Care of Lung Cancer 

Patients - Kahren White, USA 

Overcoming the Challenges of Getting Patients Through Chemo and XRT 

– Wilma Uyterlinde, Netherlands 

Importance of Exercise in Lung Cancer Treatment - Carol Michaels, USA 

14:15 - 15:45 ED 13: Education Session: The EGF Receptor and Targeting T790M 


Chairs: Michael Boyer, Australia & Matthew Gubens, USA 


 

Biological Background and Controversies - Benjamin Solomon, Australia 

72


 

 

 

Detecting T790M in Blood and Tumor - Dara Aisner, USA 

How to Make the Best Use of "Old" Drugs - Geoff Oxnard, USA 

3rd Generation EGFR TKI - Keunchil Park, South Korea 

14:15 - 15:45 Pro Con PC 03: Pro vs Con: Prophylactic Cranial Irradiation (PCI) Post 

Chemotherapy Response 

Track: Small Cell Lung Cancer / Treatment of Advanced Disease - NSCLC 

Chairs: Anthony Brade, Canada & Umberto Ricardi, Italy 

Rooms: 708 + 710 +712 

 

 

Pro - Berend Slotman, Netherlands 

Con - Nobuyuki Yamamoto, Japan 

Pro Con PC 03: Pro vs Con: Is There a Role for Radiation in Oligometastatic 

Disease? 

Track: Small Cell Lung Cancer / Treatment of Advanced Disease - NSCLC 

Chairs: Andrea Bezjak, Canada & Jin Soo Lee, South Korea 

Rooms: 708 + 710 + 712 

 

 

Pro - Cecile Le Pechoux, France 

Con - Walter Curran, USA 




15:45 - 16:45 IASLC Business Meeting 


16:45 - 18:15 Oral Session 31: PD1 Axis Inhibition 


Moderators: Jared Weiss, USA & Brendan Luey, New Zealand 


 

 

 

PD-L1 Expression as Predictive Biomarker in Patients with NSCLC: A 

Pooled Analysis - Francesco Passiglia, Italy 

Pembrolizumab for NSCLC: Immune-Mediated Adverse Events and 

Corticosteroid Use - Natasha Leighl, Canada 

Evaluation of Disease-Related Symptoms in Patients with Advanced 

Squamous Non-Small Cell Lung Cancer Treated with Nivolumab or 

Docetaxel - Richard Gralla, USA 

73


 

 

 

 

 

Discussant - Karen Kelly, USA 

High Intratumoral T Cell Infiltration Correlated with Mutational Load 

and Response to Pembrolizumab in Non-Small Cell Lung Cancer - Siwen 

Hu-Lieskovan, USA 

An Exploratory Responder Analysis of Best RECIST Response and 

Survival in Patients with Metastatic Squamous NSCLC Treated with 

Nivolumab - Diko Kazandjian, USA 

A Phase II Trial of Pembrolizumab for Untreated Brain Metastases from 

Non-Small Cell Lung Cancer - Sarah Goldberg, USA 

Discussant - David Gerber, USA 

16:45 - 18:15 Oral Session 32: EGFR WT and MT Targeting 


Moderator: Kenneth O'Byrne, Australia & David R. Gandara, USA 


Tumor Genomic Analysis from LUX-Lung 8: A Phase III Trial of Afatinib 

versus Erlotinib in Squamous Cell Carcinoma of the Lung - Glenwood 

Goss, Canada 

Long-Term Survivors with EGFR Wild-Type Advanced NSCLC Treated 

with Second-Line Erlotinib: Subgroup Analysis from WILT Study - Javier 

De Castro, Spain 

Efficacy and Safety of Necitumumab Continuation Therapy in Phase 3 

SQUIRE Study - Tudor Ciuleanu, Romania 

Discussant - Yi-Long Wu, China 

EGFR IHC and FISH Correlative Analyses (SQUIRE Trial): Necitumumab + 

Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin in 1st-Line Squamous 

NSCLC - Fred R. Hirsch, USA 

Intercalating and Maintenance Use of Gefitinib plus Chemotherapy 

versus Chemotherapy Alone in Selected Advanced NSCLC: A Phase ? 

Study - Shun Lu, China 

Randomized Phase II Trial of Sequential Gefitinib and 

Pemetrexed/Cisplatin Chemotherapy for Stage IIIB/IV Lung 

Adenocarcinoma in Never Smokers - Jin Soo Lee, South Korea 

Discussant - David R. Gandara, USA 

16:45 - 18:15 Oral Session 33: ALK 


Moderators: Shirish Gadgeel, USA 


 

 

Crizotinib Outcome and Post-Progression Management in ALK+ NSCLC: 

IFCT-1302 CLINALK - Michael Duruisseaux, France 

Time to Progression and Post-Progression Survival in ALK+ Ceritinib- 

Treated NSCLC - Geoffrey Liu, Canada 

74


 

 

 

 

 

 

Updated Efficacy/Safety Data From the Phase 2 NP28761 Study of 

Alectinib in ALK+ NSCLC - Alice Shaw, USA 

Discussant - Daniel Shao Weng Tan, Singapore 

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pre- 

Treated ALK+ NSCLC - Shirish Gadgeel, USA 

Brigatinib (AP26113) Efficacy and Safety in ALK+ NSCLC: Phase 1/2 Trial 

Results - Scott Gettinger, USA 

Clinical Activity and Safety of the ALK/ROS1 TK Inhibitor PF-06463922 in 

Advanced NSCLC - TM Bauer, USA 

Discussant - Myung-Ju Ahn, South Korea 

16:45 - 18:15 Oral Session 34: Quality/Survival/Prognosis in Localized Lung Cancer 


Moderator: Byoung Chul Cho, South Korea 

Rooms: 201 + 203 

 

 

 

 

 

 

 

 

Compliance with Follow-Up Programs After Surgery for Non-Small Cell 

Lung Cancer in the Phase III IFCT-0302 Trial - Virginie Westeel, France 

Impact of Attainment of National Comprehensive Cancer Network 

(NCCN) Quality Parameters on Patient Survival after Resection of Lung 

Cancer - Nicholas Faris, USA 

Prognostic Factors in Early Stage NSCLC: Analysis of the Placebo Group 

in the MAGRIT Study - Byoung Chul Cho, South Korea 

Discussant - Raymond Osarogiagbon, USA 

Survival Implications of Variation in the Lymph Node (LN) Count in 

ACOSOG Z0030 (Alliance) - Raymond Osarogiagbon, USA 

Impact of Surgeons' Attainment of Quality Resection Parameters on 

Non-Small-Cell Lung Cancer (NSCLC) Patients' Survival - Raymond 

Osarogiagbon, USA 

Prevalence, Prognostic Implications and Survival Modulators of 

Incompletely Resected Non-Small Cell Lung Cancer (NSCLC) in the US - 

Raymond Osarogiagbon, USA 

Discussant - Mark Krasnik, Denmark 

16:45 - 18:15 Oral Session 35: Surgical Approaches in Localized Lung Cancer 


Moderator: Marc de Perrot, Canada & John Mitchell, USA 

Rooms: 601 + 603 

 

 

 

 

Surgical Approach and Disease Recurrence in NSCLC Patients in the 

MAGRIT Study - Eric Vallieres, USA 

Wedge Resection vs Segmentectomy for Patients with T1A N0 Non- 

Small Cell Lung Cancer - Chi-Fu Yang, USA 

Salvage Surgery for Local Failures after Stereotactic Ablative 

Radiotherapy for Lung Malignancies – Berend Slotman, Netherlands 

Discussant - David Jones, USA 

75


 

 

 

 

The Role of Surgical Mediastinal Resection in CT Screen-Detected Lung 

Cancer Patients - Daniel Nicastri, USA 

Limited Resection for Non-Small Cell Lung Cancer Referring to Pathology 

- Motoki Yano, Japan 

The Feasibility and Safety of Complete VATS for NSCLC Under Non- 

Intubated Intravenous Anesthesia in Comparison with Intubated 

Anesthesia - Jun Liu, China 

Discussant - Bernward Passlick, Germany 

16:45 - 18:15 Oral Session 36: Translational Science/Radiation 


Moderator: Everett Vokes, USA & Brian Kavanagh, USA 


 

 

 

 

 

 

 

 

Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients with 

Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer - Wen 

Feng, China 

Efficacy of Chemo-Radiotherapy (CRT) in Stage III Non-Small Cell Lung 

Cancer (NSCLC) and PD-L1 Expression - Julien Adam, France 

Discussant 

Nintedanib Safely Reduces Late Radiation-Induced Lung Damage: A 

Preclinical Study with a High Precision Image-Guided Small Animal 

Irradiator - Dirk De Ruysscher, Belgium 

Results of a National Database Review of Video-Assisted Thoracoscopic 

versus Open Lobectomy after Induction Therapy - Jennifer Wilson, USA 

4D-VQ-PET/CT Imaging Allows Strong Correlation Between Radiotherapy 

Dose and Change in Lung Ventilation, Perfusion and Density - Shankar 

Siva, Australia 

Results of a National Test Run of Treatment Plans for the Standard Arm 

of a Dose Escalation Trial for Locally Advanced NSCLC - Tine Bjørn 

Nielsen, Denmark 

Discussant – Paul van Houtte, Belgium 

16:45 - 18:15 Oral Session 37: Novel Targets 


Moderator: Suresh Ramalingam, USA & Erik Thunnissen, Netherlands 


 

 

 

FISHing TRK Activation by Gene Rearrangements in Non Small Cell Lung 

Cancer - Marileila Varella-Garcia, USA 

Protein Tyrosine Phosphatase Non Receptor 11 PTPN11/Shp2 as a 

Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung 

Cancer NSCLC - Yasir Elamin, Ireland 

Discussant - Luis Raez, USA 

76


 

 

 

 

 

Comprehensive Genomic Profiling (CGP) of Advanced Cancers Identifies 

MET Exon 14 Alterations That Are Sensitive to MET Inhibitors - Ignatius 

Ou, USA 

Prevalence and Clinical Association of MET Gene Amplification in 

Patients with NSCLC: Results from the ETOP Lungscape Project - Erik 

Thunnissen, Netherlands 

Defining MET Copy Number Driven Lung Adenocarcinoma Molecularly 

and Clinically - Sinéad Noonan, USA 

Lung Cancer Mutation Consortium Pathologist Panel Evaluation of MET 

Protein - Theresa Boyle, USA 

Discussant - Glen Weiss, USA 

16:45 - 18:15 Oral Session 38: Liquid Biopsies 


Moderators: Ming Tsao, Canada & Jie Wang, China 


 

 

 

 

 

 

 

A Prospective Study of Rapid Plasma Genotyping Utilizing Sequential 

ddPCR and NGS in Newly Diagnosed Advanced NSCLC Patients - Adrian 

Sacher, USA 

Biopsy-Free Circulating Tumor DNA Assay Identifies Actionable 

Mutations in Lung Cancer - Victoria Villaflor, USA 

Assessing the Feasibility of Detecting ALK Fusions with qRT-PCR Assays 

in Cell-Free Plasma RNA - Xiaoju Max Ma, USA 

Dynamic Changes in EGFR Mutation Circulating Tumor DNA in Urine on 

Anti-EGFR Therapy - Hatim Husain, USA 

Identification of Actionable Tumor Alterations in Circulating Cell-Free 

Tumor DNA (cf DNA) Using Digital Sequencing from NSCLC Patients - 

Philip Mack, USA 

Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early 

Predictor of Clinical Response to Tyrosine Kinase Inhibitors - Rita Chiari, 

Italy 

Discussant - Geoffrey Oxnard, USA 

16:45 - 18:15 Oral Session 39: Potential Biomarkers for CT Screening 


Moderators: Kwun Fong, Australia & Nir Peled, Israel 

Rooms: 401 - 404 

 

 

 

 

Multiplexing Serum Proteins and Circulating Autoantibody for Detection 

of Lung Cancer - Bing Xia, China 

Early Detection of Lung Cancer by a FISH-Based Sputum Test - William 

Burfeind Jr., USA 

Clinical Utility of a Blood Based Circulating Tumour DNA Signature for 

the Diagnosis of Lung Cancer - Eric Lim, United Kingdom 

Discussant - Anil Vachani, USA 

77


 

 

 

 

Identification of miRNAs as Biomarkers for Early Diagnosis of Lung 

Cancers - Shirong Zhang, China 

Whole Blood microRNA Expression May Not Be Useful for Screening 

Non-Small Cell Lung Cancer - Santosh Patnaik, USA 

A Bronchial Genomic Classifier Measured in Airway Epithelial Cells 

Improves Diagnostic Sensitivity of Bronchoscopy for Lung Cancer - Anil 

Vachani, USA 

Discussant - Jill Siegfried, USA 

16:45 - 18:15 Oral Session 40: Biology 1 


Moderators: Christian Brambilla, France & Raphael Bueno, USA 

Rooms: 702 + 704 + 706 

 

 

 

 

 

 

 

 

PD-L1 Is Highly Expressed in Malignant Mesothelioma and PD-1+ 

Lymphocytes within Malignant Effusions Induce PD-L1 Expression - 

Swati Khanna, USA 

Molecular Landscape of Malignant Mesothelioma from Whole Exome 

Sequencing - Shir Kiong Lu, United Kingdom 

Combination Therapy with a CD40-Agonist and Dendritic Cell 

Immunotherapy Has Synergistic Effects in a Murine Mesothelioma 

Model - Joachim Aerts, Netherlands 

Discussant - Yoshitaka Sekido, Japan 

The Cancer Stem Cell Inhibitors VS-6063 and VS-5584 Exhibit Synergistic 

Anticancer Activity in Pre-Clinical Models of Mesothelioma - Jonathan 

Pachter, USA 

Sarcomatoid Differentiation During Progression of Malignant Pleural 

Mesothelioma - Isabelle Opitz, Switzerland 

Xpo1 Inhibition: A Promising Therapeutic Strategy in Thymic Epithelial 

Tumors - Fabio Conforti, USA 

Discussant - Thierry Marie Jahan, USA 

16:45 - 18:15 Mini Oral 26: Circulating Tumor Markers 


Moderators: Michael Macmanus, Australia & Charu Aggarwal, USA 

Rooms: 205 + 207 

 

 

 

 

Tumour Molecular Profiling and Quantitative Detection of Circulating 

Biomarkers in Patients with Non-Small Cell Lung Cancer (NSCLC) - Frank 

McCaughan, United Kingdom 

Deep Sequencing Reveals the Significance of Plasma DNA Concentration 

and Mutational Burden in Advanced Non-Small-Cell Lung Cancer 

Patients - Li Zhang, China 

Detecting C-MET Amplification in Blood and Tumor Tissue of Non-Small 

Cell Lung Cancer - meiyu Fang, China 

Discussant - Ravi Salgia, USA 

78


 

 

 

 

 

 

 

 

 

 

 

Immunophenotyping of Circulating T Cells and TILs with Chemotherapy 

and Phased Ipilimumab in Non-Small Cell Lung Cancer - Frank Dunphy, 

USA 

Cytological Criteria Based in the Characterization of CTCs for 

Assessment the Response to Erlotinib - Maria Jose Serrano, Spain 

Circulating Tumor Cells (CTC) Enrichment as Liquid-Biopsy for Molecular 

and Genomic Characterization in ALK-Rearranged (ALK+) Lung Cancer - 

Patrick Ma, USA 

A Correlative Plasma Biomarker Analysis of the Combination of 

Bevacizumab and Chemotherapy for Advanced Non-Small-Cell Lung 

Cancer - Ling-yu Ding, China 

Correlation between Circulating Tumor Biomarkers and Positron- 

Emission Tomography in Advanced Non-Small Cell Lung Cancer - Carlo 

Genova, Italy 

Discussant - Balazs Halmos, USA 

Longitudinal Monitoring of EGFR Mutations in Plasma of EGFR Mutant 

NSCLC Patients Treated with EGFR TKIs: Korean Lung Cancer Consortium 

- Ji Yun Lee, South Korea 

Circulating Tumor DNA for Noninvasive Monitoring of Non-Small Cell 

Lung Cancer Patients Receiving EGFR-Targeted Therapies - Dana Tsui, 


Serial ctDNA Assessment of Response and Resistance to EGFR-TKI for 

Patients with EGFR-L858R Mutant Lung Cancer from a Prospective Trial - 

Qing Zhou, China 

Noninvasive Identification of EGFR-T790M Mediated Resistant NSCLC 

Patients Using Plasma CfDNA - Di Zheng, China 

Discussant - Roman Perez-Soler, USA 

16:45 - 18:15 Mini Oral 27: Biology and Other Issues in SCLC 


Moderators: Paul A. Bunn Jr. USA & Julien Sage, USA 

Rooms: 605 + 607 

 

 

 

 

 

 

Investigation of Chimeric Antigen Receptor T Cells as a Novel 

Immunotherapy for SCLC - Warren Denning, USA 

RPS25 Is Essential for the Translation of the Seneca Valley Virus Genome 

and Proliferative Capacity of Small Cell Lung Cancer Cell Lines - Linde A. 

Miles, USA 

PD-L1 Expression in Small Cell Lung Carcinoma: An 

Immunohistochemical Analysis of 26 Cases Using Two Anti-PD-L1 

Antibodies - Peter Illei, USA 

PD-L1 and C-MET Expression and Survival in Patients with Small Cell 

Lung Cancer - Yun Fan, China 

Discussant - Joel Neal, USA 

Acquired Resistance Mechanisms in Small Cell Lung Cancer Mediated by 

the Cancer Stem Cell Marker Calcium Channel ?2?1 Subunit - Jie Wang, 

China 

79


 

 

A Meta-Analysis of Clinical Trials on the Risk of Hyponatraemia in Cancer 

Patients Treated with Targeted Therapies - Rossana Berardi, Italy 

Discussant - Edgardo Santos, USA 

18:30 - 20:00 Oral Session 41: Immune Biology, Microenvironment and Novel Targets 


Moderators: Sukhmani Padda, USA & Raphael Nemenoff, USA 


 

 

 

 

 

 

 

 

Tumor-Infiltrating B Lymphocytes Characterized by CD79a and MUM1 

Independently Predict Outcome in Patients with Non-Small Cell Lung 

Cancer - Sacha Rothschild, Germany 

Novel Mechanism of Immune-Tolerance and Cancer Metastasis Due to 

Aberrant Expression of Natural Killer Immunoglobulin-Like Receptors 

(KIRs) - Daniel Chan, USA 

Myeloid Derived Supressor Cells and Their Clinical Relevance in Non- 

Small Cell Lung Cancer - Oscar Arrieta Rodriguez, Mexico 

Discussant - Naiyer Rizvi, USA 

Targeting Phosphatidylserine-Mediated Immune Suppression Enhances 

the Efficacy of Immune Checkpoint Blockade in Pre-Clinical Tumor 

Models - Rolf Brekken, USA 

Transcriptional Profiling of Distinct Macrophage Subsets in Lung Tumor 

Microenvironment Reveals Their Functional Heterogeneity - Joanna 

Poczobutt, USA 

The Identification of Therapeutic Targets in Lung Cancer Based on 

Transcriptomic and Proteomic Characterization of Cancer-Testis 

Antigens - Dijana Djureinovic, Sweden 

Discussant - Roy Herbst, USA 

18:30 - 20:00 Oral Session 42: Drug Resistance 


Moderators: Robert Doebele, USA & James DeGregori, USA 


 

 

 

 

 

ALK-Rearranged NSCLC Adaptive Cell Plasticity with Early Onset TGFb2 

Mediated Precision Drug Escape through PRC-2 Epigenetic 

Reprogramming - Patrick Ma, USA 

Qualitative and Quantitative Heterogeniety in Acquiring Resistance to 

EGFR Kinase Inhibitors in Lung Cancer - Kenichi Suda, Japan 

Discussant - Lynn Heasley, USA 

Rictor Alterations Elicit Mechanisms of Survival Advantage and 

Resistance to Targeted Therapy in Non-Small Cell Lung Cancer (NCSLC) - 

Julie Izzo, USA 

SMARCA4/BRG1 Is a Biomarker for Predicting Efficacy of Cisplatin-Based 

Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) - Erica Bell, USA 

81


 

 

Cancer Stem Cells: Targeting Aldehyde Dehydrogenase 1 (ALDH1) as a 

Novel Strategy in Cisplatin Resistant Non-Small Cell Lung Cancer? - 

Martin Barr, Ireland 

Discussant - Seiji Yano, Japan 

18:30 - 20:00 Oral Session 43: Enhancing Physical Wellbeing in Lung Cancer 


Moderators: Gleneara Bates, USA & Mary Hesdorffer, USA 

Rooms: 102 + 104 + 106 

Guideline for Patient Information on Enhanced Recovery in Thoracic 

Surgery - Jenny Mitchell, United Kingdom 

Which Patients Are Assessed by a Lung Cancer Nurse Specialist: A UK 

National Lung Cancer Audit Study - Angela Tod, United Kingdom 

The Rationale of Exercise in Patients with Inoperable Lung Cancer - 

Morten Quist, Denmark 

Discussant - Marianne Davies, USA 

Development and Evaluation of Health and Wellbeing Events for People 

Affected by Lung Cancer - Sally Moore, United Kingdom 

Improving Surviorship through Prehabiltiation for Thoracic Cancer 

Patients - Karen Clayton, United Kingdom 

Performance Status (PS): Is There a Correlation Between Doctor and 

Patient? - Karen Clayton, United Kingdom 

Discussant - Beth Ivimey, Australia 

18:30 - 20:00 Mini Oral 29: Meta Analyses and Trial Conduct 


Moderator: Daniel Morgensztern, USA & Mary Redman, USA 


 

 

 

 

 

 

 

Squamous Cell Carcinoma of Lung in the United States: Analysis of the 

National Cancer Database (NCDB) - Madhusmita Behera, USA 

Effect of Statins and Metformin on Survival in Patients with Non-Small 

Cell Lung Cancer - Narjust Duma, USA 

Prognostic Value of Biomarkers Associated with Glucose Metabolism 

and Systemic Inflammation in Advanced On-Small Cell Lung Cancer 

(NSCLC) - Mary Fidler, USA 

The Use of Metformin and Proper Glycemic Control Are Associated with 

Improved Survival in Non-Small Cell Lung Cancer Patients - Oscar Arrieta 

Rodriguez, Mexico 

Discussant - David Stewart, Canada 

Are Clinical Trial Eligibility Criteria an Accurate Reflection of a Real 

World Population of Advanced Lung Cancer Patients? - Paul Wheatley- 

Price, Canada 

CNS Disease Enrollment Criteria for NSCLC Drug Trials - Caroline 

McCoach, USA 

82


 

 

 

 

 

 

 

 

Innovation in Non-Small Cell Lung Cancer (NSCLC): Where Are the 

Clinically Meaningful Outcomes? - Lisa Hess, USA 

Recommendations for Standardized Efficacy Data Specifications in Lung 

Cancer - Sean Khozin, USA 

Discussant - Mary Redman, USA 

Assessing Patient-Reported Symptoms in Non-Small Cell Lung Cancer 

Clinical Trials - Alicyn Campbell, USA 

Patients with Advanced Non-Small Cell Lung Cancer: Are Research 

Biopsies a Barrier to Participation in Clinical Trials? - Charles Lim, 

Canada 

Safety and Clinical Implications of Repeat Tumor Biopsy (RTB) in 

Patients with Advanced Lung Cancer: A Retrospective Institutional Study 

- Eberechi Agwa, USA 

Using a Bayesian Adaptive Phase II Trial Design to Test Multiple Genetic- 

Marker-Directed Drugs in the National Lung Matrix Trial - Lucinda 

Billingham, United Kingdom 

Discussant - Barbara Gitlitz, USA 

18:30 - 20:00 Mini Oral 30: New Kinase Targets 


Moderators: Keunchil Park, South Korea & Miguel Villalona, USA 


Oncolytic Reovirus in Combination with Paclitaxel/Carboplatin in NSCLC 

Patients with Ras Activated Malignancies, Long Term Results - Miguel 

Villalona, USA 

Phase II Study of Defactinib, VS-6063, a Focal Adhesion Kinase (FAK) 

Inhibitor, in Patients with KRAS Mutant Non-Small Cell Lung Cancer 

(NSCLC) - David Gerber, USA 

Smoking Predicts Sensitivity to PARP Inhibitor, Veliparib, in Advanced 

NSCLC Patients - Normand Blais, Canada 

A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the 

Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: 

ECOG-ACRIN E1512 - Joel Neal, USA 

Discussant - Nathan Pennell, USA 

Activity of AUY922 in NSCLC Patients With EGFR Exon 20 Insertions - 

Zofia Piotrowska, USA 

Crizotinib in Patients with ROS1 NSCLC. Preliminary Results of the AcSé 

Trial - Denis Moro-Sibilot, France 

ROS1 Resistance to Crizotinib Is Mediated by an Activating Mutation in 

c-KIT - Rafal Dziadziuszko, Poland 

Clinical Response to Entrectinib in a Patient with NTRK1-Rearranged 

Non-Small Cell Lung Cancer (NSCLC) - Anna Farago, USA 

 

 

Discussant - Daniel Tan, Singapore 

Efficacy and Safety of Dovitinib in Advanced Squamous Cell Lung Cancer 

with FGFR1 Amplification: A Single-Arm, Phase II Study - Sung Hee Lim, 

South Korea 

83


 

 

 

A Phase II Trial of Pictilisib with Chemotherapy in First-Line Non- 

Squamous NSCLC - Benjamin Besse, France 

A Phase II Trial of Pictilisib with Chemotherapy in First-Line Squamous 

NSCLC - David Spigel, USA 

Discussant - John Heymach, USA 

18:30 - 20:00 Mini Oral 31: ALK 


Moderators: Shakun Malik, USA & Sai-Hong Ou, USA 


Diverse Characteristics of ALK+ NSCLC Patients in the United States - 

Edmond Bendaly, USA 

Real-World Characteristics and Outcomes for ALK+ NSCLC in Korea - 

Keunchil Park, South Korea 

Crizotinib Outcomes in ALK-Positive Advanced NSCLC Patients with Brain 

Metastases - Keith Davis, USA 

Intracranial Efficacy of First-Line Crizotinib vs. Chemotherapy in ALK- 

Positive NSCLC - Benjamin Solomon, Australia 

Discussant - Alice Shaw, USA 

Crizotinib and Interstitial Lung Disease: Systematic Review of Four 

Clinical Trials - Ken Yoneda, USA 

Cardiac Toxicity of Crizotinib Therapy in Advanced ALK-Rearranged Non- 

Small Cell Lung Cancer - Yan Zhang, China 

Real-World Persistence and Adherence to Crizotinib in over 3800 US 

Patients - Ruslan Horblyuk, USA 

Association of Crizotinib Toxicity with Pharmacokinetics and 

Pharmacogenomics in Non-Small Cell Lung Cancer Harboring ALK Fusion 

Gene - Yuichi Tambo, Japan 

 

 

 

 

 

 

Discussant - Sai-Hong Ou, USA 

Comparison of Different ALK Tests in Non-Small Cell Lung Cancer 

(NSCLC) Patients before and after Crizotinib and Their Clinical Outcome - 

Anthonie Van Der Wekken, Netherlands 

Quality of Life for Crizotinib vs. Chemotherapy in Asian ALK-Positive 

NSCLC Patients - Fiona Blackhall, United Kingdom 

Symptoms and QOL with Ceritinib in ALK+ NSCLC Patients with/without 

Brain Metastases - Lucio Crinò, Italy 

PROs with Ceritinib in ALKi-Naive ALK+ NSCLC Patients with and without 

Brain Metastases - Keunchil Park, South Korea 

Discussant - Leora Horn, USA 

18:30 - 20:00 Mini Oral 32: Topics in Localized Lung Cancer 


Moderators: Daniel Boffa, USA & Thomas D'Amico, USA 

Rooms: 201 + 203 

84


 

 

 

 

 

 

 

 

 

 

 

 

Computed Tomography Lymphography by Transbronchial Injection of 

Iopamidol for Preoperative Non-Small Cell Lung Cancer Patients - 

Hiromitsu Takizawa, Japan 

Characteristics of Non-Small Cell Lung Cancer (NSCLC) Patients Who 

Underwent Curative-Intent Surgical Resections in China - Jian Zhou, 

China 

Accuracy of Respiratory Dynamic Computed Tomography for the 

Detection of Pleural Adhesions - Junko Tokuno, Japan 

Clinico-Pathological Correlations and the Role of Brain MRI in Combined 

Clinical Staging for Resectable Lung Cancer - Wael Hanna, Canada 

Clinical Impacts of Tumor Hypoxia Imaging with FAZA and ATSM PET in 

NSCLC - Tomonari Kinoshita, Japan 

A Phase I Feasibility Study of Kilovoltage Intrafraction Monitoring for 

Lung Cancer - Fiona Hegi-Johnson, Australia 

Identification of a Meta-Gene Network Associated with Metformin 

Sensitivity and Recurrence in Stage I Non-Small Cell Lung Cancer - Casey 

Frankenberger, USA 

The Combination of Serum Biomarkers CYFRA 21-1 and CEA in the 

Prognostication of Early Stage Non-Small Cell Lung Cancer (NSCLC) - 

Thomas Muley, Germany 

10 Years of National Lung Cancer Audit in the UK - Michael Peake, 


Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell 

Lung Cancer Patients with or without Icotinib Consolidation Therapy - 

Siyang Feng, China 

Racial/Ethnic and Gender Differences in Treatment and Survival of Early- 

Stage Non-Small Cell Lung Cancer in an Integrated Health Care System - 

Lori Sakoda, USA 

Primary Early-Stage Lung Cancer Following Head and Neck Cancer: A 

Population Based Study of Treatment and Survival in the Netherlands - 

Berend Slotman, Netherlands 

18:30 - 20:00 Mini Oral 33: Radiotherapy and Complications 


Moderator: Stuart Burri, USA 

Rooms: 601 + 603 

Prospective Phase II Trial of SBRT for Centrally-Located Lung Cancer - 

Jeffrey Bradley, USA 

Dose-Escalated Radiotherapy for NSCLC: Heart Doses versus Survival in 

IDEAL-CRT - Sindu Vivekanandan, United Kingdom 

Heart Dose Is Associated with Shorter Overall Survival for Patients 

Treated with Chemo-Radiation for Locally Advanced NSCLC - Jan-Jakob 

Sonke, Netherlands 

Acute Radiation Pneumonitis in Lung Cancer Treated with Volumetric 

Modulated Arc Therapy - Bing Xia, China 

Discussant – David Raben, USA 

85


 

 

 

 

 

 

 

 

 

Prospective Monitoring of Lung Function Test with CO and NO Diffusion 

during Thoracic Radiotherapy: Preliminary Results of the CONORT Study 

- Sébastien Couraud, France 

A Restrospective Study of Shrinking Field Radiation Therapy in 

Chemoradiothrapy for Stage III Non-Small Cell Lung Cancer - Yaping Xu, 

China 

Feasibility & Efficacy of Hypofractionated Radiotherapy in LA-NSCLC: A 

Phase II Study - Sushmita Pathy, India 

Impact of Tumor Regression and Need for Re-Plan during Radiation 

Therapy for Stage IIIB Lung Cancer: Dosimetric Comparison between 

IMRT and IMPT - Heerim Nam, South Korea 

Discussant - Dirk De Ruysscher, Belgium 

Locally Advanced NSCLC Elderly Patients Assessed by Multidimensional 

Geriatric Assessment and Treated with Concurrent Chemoradiation - 

Ernest Nadal, Spain 

Analysis of Acute Radiation-Induced Esophagitis in NSCLC Pts Using 

Lyman NTCP Model - Jian Zhu, China 

Locally Advanced NSCLC: Patient Preferences Regarding Prophylactic 

Cranial Irradiation - A Discrete Choice Experiment - Margot Lehman, 

Australia 

Discussant - Kenneth Rosenzweig, USA 

18:30 - 20:00 Mini Oral 34: RNA and miRNA 


Moderators: Céline Mascaux, France & Luhua (Jingbo) Wang, China 

Rooms: 205 + 207 

 

 

 

 

 

 

 

 

 

 

MicroRNA Profiling of a Familial Primary Pulmonary Enteric 

Adenocarcinoma - Ingrid Garajová, Italy 

Prognostic Impact of Bcl-2 Depends on Tumor Histology and Expression 

of MALAT-1 lncRNA in NSCLC - Rainer Wiewrodt, Germany 

Novel microRNA Prognostic Signature in Malignant Pleural 

Mesothelioma - Francesco Grossi, Italy 

Serum MicroRNA-139-5p Is a Biomarker of Bone Metastasis in Lung 

Cancer Patient - Song Xu, China 

Discussant - Christopher Rivard, USA 

MicroRNA 10b, 27a and 27b Are Upregulated in Lung Cancer Cell with 

Epidermal Growth Factor (EGFR) Mutation Resistant to EGFR TKI - Chao 

Huang, USA 

A Novel microRNA Signature Associated with Cisplatin Resistance in 

NSCLC - Martin Barr, Ireland 

MiR-33B Inhibit EMT Through Wnt/β-Catenin/ZEB1 Pathway in Lung 

Adenocarcinoma - Min Li, China 

The Long Non-Coding RNA AK126698 Modulates Wnt/β-Catenin 

Signaling Through FZD-8 Silencing in Non-Small-Cell Lung Cancer - xiao 

Fu, China 

Discussant - Glen Reid, Australia 

86


 

 

 

 

 

Identification and Functional Characterization of Non-Small Cell Lung 

Cancer-Associated Splice Variants and Splicing Factors - Ruben Pio, 

Spain 

Oncofetal miRNA Expression Inactivates Nuclear Factor I/B, a Critical 

Regulator of Lung Development and Lung Adenocarcinoma 

Pathogenesis - Daiana Becker-Santos, Canada 

Long Noncoding RNA BC070487 Represses ZNFX1 during Tobacco- 

Induced Lung Carcinogenesis - Sichuan Xi, USA 

Biological Role of Prognostic MicroRNAs (MiRNAs) in Squamous Lung 

Cancer Cell Lines - Martyna Filipska, Poland 

Discussant - David Beer, USA 

18:30 - 20:00 Mini Oral 35: Biology 


Moderators: Theresa Boyle, USA & Mark Kris, USA 


Genetic Alterations in the Fanconi Anemia Pathway in Lung Cancers - 

Wenrui Duan, USA 

Inhibitor of Differentiation 1 (Id-1) Gene Silencing Reduces Liver 

Metastases Formation in a NSCLC Animal Model - Ignacio Gil-Bazo, 

Spain 

N-Myc Downstream Regulated Gene 1(NDRG1) Promotes the Stem-Like 

Properties of Lung Cancer Cells Through Stabilized C-Myc - kai Wang, 

China 

Degradation of FGFR1/Akt/Src/C-Raf/Erk by Arsenic Trioxide and FGFR 

Inhibitor in Squamous Cell Lung Cancer - Sze Kwan Lam, Hong Kong 

Discussant - Mark Kris, USA 

Genome-Wide Methylome Alterations in Lung Cancer - Simon Spivack, 

USA 

ATM Mutations in Cancer Cell Lines Predict Higher Mutation Rates and 

Genetic Instability - D. Gwyn Bebb, Canada 

Functional Role of Cancer Associated Fibroblasts in Non-Small Cell Lung 

Cancer Patients - Roya Navab, Canada 

Sonic Hedgehog Is Required for Tumor Progression in a Mouse Model of 

Small Cell Lung Cancer - Anette Szczepny, Australia 

Discussant - Bruce Johnson, USA 

Mutant ARAF Drives Lung Carcinogenesis Through a Distinct Oncogenic 

Mechanism - Luiz H. Araujo, USA 

Stratifin Accelerates Progression of Lung Adenocarcinoma at an Early 

Stage - Aya Shiba, Japan 

Targeting Cancer Stem Cell Factor BMI1 to Sensitize Non-Small Cell Lung 

Cancer to Chemotherapy and Radiation Therapy - Kunal Chaudhary, 

USA 

Microthrombosis Enhances Extravasation via Myeloid Hypoxia-Inducible 

Factors - Colin Evans, United Kingdom 

Discussant – Jonathan Goldman, USA 

87


18:30 - 20:00 Mini Oral 36: Imaging and Diagnostic Workup 


Moderator: Feng-Ming (Spring) Kong, USA 

Rooms: 401 - 404 

Three-Dimensional Quantitative Computed Tomography Evaluation of 

Pulmonary Adenocarcinoma Using Image-Analysis Software - Kazunori 

Hata, Japan 

Newly Detected Solid Nodules at Incidence CT Lung Cancer Screening 

Rounds: Occurrence and Lung Cancer Probability - Marjolein 

Heuvelmans, Netherlands 

Multi-Nodularity in Baseline CT Lung Cancer Screening and Relationship 

with Lung Cancer Probability - Marjolein Heuvelmans, Netherlands 

Automated Measurement of Malignancy Risk of Lung Nodule Detected 

by Screening Computed Tomography - Alexander Ritchie, Australia 

Computer Vision Tool and Technician as First Reader of Lung Cancer 

Screening CT - Alexander Ritchie, Australia 

Discussant - Matthew Steliga, USA 

Diagnostic Value of Electromagnetic Navigation Bronchoscopy for 

Peripheral Pulmonary Lesions : A Randomized Controlled Trial - Sun 

Jiayuan, China 

18F-FDG PET Imaging Utilization in the National Lung Screening Trial - 

Viswam Nair, USA 

CT-Guided Cutting Needle Lung Biopsy Using "Liquid Withdraw" 

Technique: Prominently Reduced Incidence of Pneumothorax - Rutian 

Li, China 

Discussant - Dominique Grunenwald, France 

Pre-Operative Fine Needle Aspiration (FNA) for Diagnosis of Suspected 

Early Stage Lung Cancer Reduces Non-Malignant Resection Rate - Julie 

Barta, USA 

Diagnosis of Peripheral Lung Nodules: Cost Analysis of EMB/EBUS 

Compared to TTNB - K. Adam Lee, USA 

Quantitative Computed Tomography as Predictor of Cardiopulmonary 

Complication after Lobectomy for Lung Cancer in COPD Patients - 

Yoshiyuki Yasuura, Japan 

Improving Pathways to Early Lung Cancer Diagnosis: Process Mapping 

and Qualitative Analysis - Nicole Rankin, Australia 

18:30 - 20:00 Mini Oral 37: SCLC Therapy 


Moderators: David Ettinger, USA & George Simon, USA 

Rooms: 605 + 607 

 

Chk1 Inhibition Enhances Cisplatin Cytotoxicity Regardless of p53 Status 

in Human Small Cell Lung Cancer Cells - Wei-Hsun Hsu, USA 

88


 

 

 

 

 

 

 

 

 

 

 

 

The Novel HSP90 Inhibitor-SN-38 Conjugate (STA-12-8666), Is Highly 

Active in Preclinical Models of Small Cell Lung Cancer (SCLC) - Yanis 

Boumber, USA 

Survival after Surgery for pN1 and pN2 Small Cell Lung Cancer: A 

Comparison with Surgical Treatment of Non-Small Cell Lung Cancer - 

Chi-Fu Yang, USA 

Discussant - M Catherine Pietanza, USA 

Carfilzomib, Carboplatin and Etoposide for Previously Untreated 

Extensive-Stage Small Cell Lung Cancer: Initial Results from a Phase 1b/2 

Study - Firas Badin, USA 

Randomized Phase II Trial of CODE or Amrubicin Plus Cisplatin 

Chemotherapy after Chemoradiotherapy for Limited-Disease Small Cell 

Lung Cancer - Ikuo Sekine, Japan 

PCI Survival Improvement for Extensive Stage SCLC Limited to Patients 

on Maintenance Systemic Therapy: A Secondary Analysis of CALGB 

30504 - Joseph Salama, USA 

Pazopanib as Second Line Treatment of Platinum Sensitive SCLC 

Patients: A Multicenter Phase II Trial of the Hellenic Oncology Research 

Group - Athanasios Kotsakis, Greece 

Discussant - Taofeek Owonikoko, USA 

Factors Associated with Severe Pneumonitis for Limited Stage Small Cell 

Lung Cancer - Ritsuko Komaki, USA 

Inter-Observer Variability in Hippocampus Delineation on MRI Scans for 

Hippocampal Avoidance Prophylactic Cranial Irradiation Trial - Jose 

Belderbos, Netherlands 

Survival Trends of Small Cell Lung Cancer (SCLC) in the United States: A 

SEER Database Analysis - Lata Nawal, USA 

Discussant - Nevin Murray, Canada 

18:30 - 20:00 Mini Oral 38: Biology and Prognosis 


Moderator: Ryosuke Tsuchiya, Japan & Murry Wynes, USA 

Rooms: 702 + 704 + 706 

 

 

 

 

 

FAK Inhibitor VS-6063 Targets Mesothelioma Cancer Stem Cells: 

Rationale for Maintenance Therapy after Conventional Chemotherapy - 

David Weaver, USA 

BAP1 Inactivation in Mesothelioma Is Highly Prevalent - Marjorie 

Zauderer, USA 

Validation of a Specific Missense GTF2I Mutation in More Indolent 

Thymic Epithelial Tumours - Spyridon Gennatas, United Kingdom 

BRCA1/OCT1/MAD2L1 Axis Regulates a Bifurcating Apoptotic Pathway 

Induced by Vinorelbine in Mesothelioma - Sara Busacca, United 

Kingdom 

Discussant - Jan Van Meerbeeck, Belgium 

89


 

 

 

 

 

 

 

 

 

 

FP1039/GSK3052230 with Chemotherapy in Patients with Fibroblast 

Growth Factor (FGF) Pathway Deregulated Squamous NSCLC or MPM - 

Pilar Garrido, Spain 

RITA Enhances Mithramycin-Mediated Growth Arrest and Apoptosis of 

Malignant Pleural Mesothelioma Cells In-Vitro and In-Vivo - Mahadev 

Rao, USA 

Contemporary Analysis of Prognostic Factors in Patients with 

Unresectable Malignant Pleural Mesothelioma (MPM) - Andrea Bille, 

USA 

The Prognostic Significance of Nodal Metastatic Burden in Survival 

following Radical Surgery for Malignant Pleural Mesothelioma - Annabel 

Sharkey, United Kingdom 

Discussant - Jonathan Riess, USA 

Tumor Volume and Epithelioid Differentiation Are Independent 

Predictors of Survival in Malignant Pleural Mesothelioma - Diana 

Kircheva, USA 

Multiplex Immunofluorescence Identifies Differences in Immune 

Microenvironment & Prognostic Biomarkers between Mesothelioma 

Subtypes - Tanguy Seiwert, USA 

Survival Outcomes in Malignant Pleural Mesothelioma Patients Fit for 

Surgery According to Type of Procedure and Completeness of Resection 

- Maurizio Infante, Italy 

Surgery and Not Radiation Improves Survival in Malignant Pleural 

Mesothelioma - Andrea Wolf, USA 

Discussant - Harvey Pass, USA 

90

Sunday September 6 2015

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?